---
document_datetime: 2023-09-21 19:59:18
document_pages: 80
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/venclyxto-h-c-4106-ii-0023-g-epar-assessment-report-variation_en.pdf
document_name: venclyxto-h-c-4106-ii-0023-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 107.5529894
conversion_datetime: 2025-12-28 18:41:18.447045
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

30 January 2020 EMA/166265/2020 Committee for Medicinal Products for Human Use (CHMP)

## CHMP group of variations including an extension of indication assessment report

Invented name: Venclyxto

International non-proprietary name: venetoclax

Procedure No. EMEA/H/C/004106/II/0023/G

Marketing authorisation holder (MAH) AbbVie Deutschland GmbH &amp; Co. KG

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6     |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                   | 7                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................7 |
| 2.2. Non-clinical aspects..............................................................................................9   |                                                                                                           |
| 2.2.1. Introduction......................................................................................................9 |                                                                                                           |
| 2.2.2. Pharmacology                                                                                                        | ...................................................................................................9      |
| 2.2.3. Toxicology........................................................................................................9 |                                                                                                           |
| 2.2.4. Ecotoxicity/environmental risk assessment.........................................................                  | 16                                                                                                        |
| 2.2.5. Discussion on non-clinical aspects                                                                                  | ..................................................................... 17                                  |
| 2.2.6. Conclusion on the non-clinical aspects                                                                              | ............................................................... 19                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 19     |
| 2.3.1. Introduction....................................................................................................    | 19                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 20           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 27                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 33                                                                                                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 34                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 34     |
| 2.4.1. Dose response study(ies)                                                                                            | ................................................................................. 34                      |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 35  |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 56                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 58                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 58   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 68                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................         | 68                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 69  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 69                |
| 2.7. Update of the Product information........................................................................             | 75                                                                                                        |
| 2.7.1. User consultation                                                                                                   | ............................................................................................ 75           |
| 3. Benefit-Risk Balance .............................................................................                      | 75                                                                                                        |
| 3.1. Therapeutic Context ...........................................................................................       | 75                                                                                                        |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 75               |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 75                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................      | 76                                                                                                        |
| 3.2. Favourable effects..............................................................................................      | 76                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 76                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................       | 77                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 77                                                              |
| 3.6. Effects Table......................................................................................................   | 77                                                                                                        |
| 3.7. Benefit-risk assessment and discussion.................................................................               | 78                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 78                                                                                                        |
| 3.7.2. Balance of benefits and risks                                                                                       | ............................................................................ 78                           |

<div style=\"page-break-after: always\"></div>

| 3.8. Conclusions .......................................................................................................   | 79   |
|----------------------------------------------------------------------------------------------------------------------------|------|
| 4. Recommendations.................................................................................                        | 79   |
| 5. EPAR changes .......................................................................................                    |      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

1L

first line/previously untreated

AE

adverse event

AESI

adverse event of special interest

ASO-PCR

allele-specific oligonucleotide polymerase chain reaction

BCL-2

B-cell lymphoma-2

BR

bendamustine + rituximab

CHMP

Committee for Medicinal Products for Human Use

CIRS

Cumulative Illness Rating Scale

Clb

Chlorambucil

CLL

chronic lymphocytic leukemia

CMH

Cochran-Mantel-Haenszel

CR

complete response

CrCl

creatinine clearance

CRi

complete response with incomplete bone marrow recovery

CSR

clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

DI

Dose Intensity

EC

European Commission

ECOG

Eastern Cooperative Oncology Group

EFD

embryo-foetal development

EFS

Event free survival

EMA

European Medicines Agency

EORTC QLQ-C30

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30

EOT

end of treatment

EQ-5D-3L

EuroQoL 5-Dimension questionnaire

ESMO

European Society for Medical Oncology

EU

European Union

EuroQoL

European Quality of Life

FCR

fludarabine + cyclophosphamide + rituximab

FDA

US Food and Drug Administration

G

obinutuzumab (GAZYVA ® /Gazyvaro  )

GCP

Good Clinical Practice

GClb

obinutuzumab in combination with chlorambucil

GD

Gavage day

HR

hazard ratio

ICH

International Conference on Harmonisation

IDMC

Independent Data Monitoring Committee

IgVH/IGHV

immunoglobulin heavy chain variable region

IRC

Independent Review Committee

IRR

infusion-related reaction

ITT

intent-to-treat

iwCLL

international workshop on Chronic Lymphocytic Leukemia

K-M

Kaplan-Meier

MDASI-CLL

M.D. Anderson Symptom Assessment Inventory ⎯ CLL

MRD

minimal residual disease

MTD

maximum tolerated dose

NCCN

National Comprehensive Cancer Network

OR

overall response

ORR

overall response rate

OS

overall survival

PCR

Polymerase Chain Reaction

PFS

progression-free survival

PIP

Pediatric Investigation Plan

PK

Pharmacokinetics

popPK

population pharmacokinetics

PR

partial response

PRO

patient-reported outcome

PT

preferred term

QLQ-C30

Quality of Life Questionnaire-Core 30

R/R

relapsed or refractory

RMP

Risk management plan

SAE

serious adverse event

SLL

small lymphocytic lymphoma

SOC

System Organ Class

TLS

tumor lysis syndrome

VEN

Venetoclax

VEN+G

venetoclax in combination with obinutuzumab

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, AbbVie Deutschland GmbH &amp; Co. KG submitted to the European Medicines Agency on 28 June 2019 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I                  |
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I                  |

Extension of indication to include, in combination with an anti -CD20 antibody (obinutuzumab), treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) for Venclyxto based on the results of the pivotal CLL14/BO25323 phase 3 study; consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC and corresponding sections of the PL have been revised. The updated RMP version 5.1 has been submitted. Additionally, the SmPC section 5.3 has been updated based on the results of a 4-week dose ranging study, a 6-month carcinogenicity study and two embryo-foetal development (EFD) studies in mice. Minor editorial changes have been introduced throughout the Product Information.

The group of variations requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0246/2019 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0246/2019 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 9 November 2017 (EMA/CHMP/SAWP/716506/2017).

The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Filip Josephson

| Timetable                                                    | Actual dates      |
|--------------------------------------------------------------|-------------------|
| Submission date                                              | 28 June 2019      |
| Start of procedure:                                          | 20 July 2019      |
| CHMP Rapporteur Assessment Report                            | 13 September 2019 |
| CHMP Co-Rapporteur Assessment Report                         | 13 September 2019 |
| PRAC Rapporteur Assessment Report                            | 19 September 2019 |
| PRAC members comments                                        | 25 September 2019 |
| Updated PRAC Rapporteur Assessment Report                    | 26 September 2019 |
| PRAC Outcome                                                 | 3 October 2019    |
| CHMP members comments                                        | 7 October 2019    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report         | 10 October 2019   |
| Request for supplementary information (RSI)                  | 17 October 2019   |
| CHMP Rapporteur Assessment Report                            | 20 December 2019  |
| PRAC Rapporteur Assessment Report                            | 3 January 2020    |
| PRAC members comments                                        | 8 January 2020    |
| Updated PRAC Rapporteur Assessment Report                    | 9 January 2020    |
| PRAC Outcome                                                 | 16 January 2020   |
| CHMP members comments                                        | 20 January 2020   |
| Updated CHMP Rapporteur Assessment Report                    | 23 January 2020   |
| Opinion                                                      | 30 January 2020   |
| The CHMP adopted a report on similarity on date (Appendix I) | 30 January 2020   |

## 2. Scientific discussion

## 2.1. Introduction

CLL remains the most prevalent chronic leukaemia in clinical practice. The treatment landscape for firstline CLL is evolving. Deep remissions and clinically significant PFS can be achieved with chemo-immunotherapy combinations, such as fludarabine-based regimens, but these intensive regimens cannot be used for the majority of newly diagnosed patients with CLL who are older and/or have comorbidities. Such patients require more effective but less toxic regimens. More tolerable regimens, such as anti-CD20 antibodies plus chlorambucil have improved outcomes of patients with CLL and comorbidities compared with previous standard-of-care (chlorambucil). Chlorambucil + obinutuzumab has shown improved PFS and OS (Goede et al. 2014, 2018), and is now the standard of care in older patients with comorbidities. However, many only achieve a partial response and no MRD negativity.

<div style=\"page-break-after: always\"></div>

The current International Working Group for CLL (iwCLL) 2018 guidelines recommend active surveillance until disease-related symptoms develop. The prognostic factors in CLL are largely based on recurrent molecular and cytogenetic abnormalities. The role of MRD negativity in achieving deeper remissions and longer PFS (and ultimately overall survival) is taking centre stage in clinical trials.

Both NCCN (latest version:2020) and ESMO (2015, with an update in 2017) segregate patients with and without del(17p)/TP53mut and fit from unfit:

Figure 1 &gt;AlgorithmforFront-line Treatment

<!-- image -->

## About the product

Venetoclax is a selective, orally bioavailable, small molecule, B-cell lymphoma-2 (BCL-2) inhibitor that restores programmed cell death (apoptosis) in cancer cells.  BCL-2 over expression is a major contributor to the pathogenesis of some types of lymphoid malignancies, including chronic lymphocytic laeukemia (CLL).

The approved indications are:

Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

Venclyxto monotherapy is indicated for the treatment of CLL:

- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

The proposed indication is: Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).

Venetoclax is given for a total of 12 cycles, each cycle consisting of 28 days: 6 cycles in combination with obinutuzumab, followed by 6 cycles of venetoclax as a single agent.

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

The subject of this grouped type II variation application is to extend the approved indication of venclyxto, in combination with the anti -CD20 antibody obinutuzumab, as a frontline treatment of CLL.

Further, the MAH submitted new non-clinical carcinogenicity and embryo foetal development (EFD) data. An overview of the new non-clinical studies is presented below.

Table 1: Overview of new non-clinical toxicology studies with venetoclax and M27

| Study type/duration                                   | Species/strain                                                    | Route of administration   | Dose (mg/kg/day)                                                                                  | GLP   | Reference   |
|-------------------------------------------------------|-------------------------------------------------------------------|---------------------------|---------------------------------------------------------------------------------------------------|-------|-------------|
| Repeat-dose toxicity                                  |                                                                   |                           |                                                                                                   |       |             |
| 4-week repeat-dose toxicity study with M27            | Mouse/ CByB6F1- Tg(HRAS)2Jic wild type                            | Oral                      | M27: 0, 30, 100, 300                                                                              | Yes   | R&D/16/0143 |
| Carcinogenicity                                       |                                                                   |                           |                                                                                                   |       |             |
| 26-week carcinogenicity study with venetoclax and M27 | Mouse/ Taconic Model 001178-T (hemizygous), CByB6F1- Tg(HRAS)2Jic | Oral                      | Venetoclax: 0, 40, 130, 400 M27: 0, 250 N-nitroso-N- methylurea (positive control) 75 single dose | Yes   | R&D/18/0248 |
| Reproductive and developmental toxicity               |                                                                   |                           |                                                                                                   |       |             |
| DRF EFD with M27, 10 days (GD 6-15)                   | Mouse/CD1                                                         | Oral                      | M27: 0, 30, 100, 250                                                                              | No    | R&D/18/0477 |
| EFD with M27, 10 days (GD 6-15)                       | Mouse/CD1                                                         | Oral                      | M27: 0, 30, 250                                                                                   | Yes   | R&D/18/0648 |

## 2.2.2. Pharmacology

No new non-clinical pharmacology studies have been submitted (see discussion on non-Clinical aspects).

## 2.2.3. Toxicology

## Single dose toxicity

No new single-dose toxicity studies have been submitted (see discussion).

<div style=\"page-break-after: always\"></div>

## Repeat dose toxicity

Table 2 : 4-week repeat-dose toxicity study with M27

| Report number/GLP /Duration   | Species/Sex/ Number/Group                                                                       | Dose (mg/kg/day)/ Route                                                                              | NOAEL (mg/kg/day)   |
|-------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------|
| R&D/16/0143 GLP 4-weeks       | Mouse wild-type (non- transgenic littermates) CByB6F1-Tg(HRAS)2Jic 10/sex/group 10/sex/group TK | 0 (control), M27: 30, 100, 300 Oral gavage Control: copovidone in 0,1% antifoam C in purified water. | 300 mg/kg/day       |

Mortality: none

Food consumption/body weight: ≥30 mg/kg/day; decreased food consumption in males (ranging from 7,2 to -12,6% compared to control). Body weight gain in males at 30 and 300mg/kg/day was less than that of control (-36.4% and -58.2%, respectively).

Haematology: ≥30mg/kg/day; decrease in mean lymphocyte count in males (-24% to -40% compared to control). 300mg/kg/day; minimal decrease in haemoglobin in females (-4%).

There were no M27-related clinical observations and no M27-related changes in clinical chemistry, organ weight, gross or histopathology.

## Genotoxicity

No new genotoxicity studies have been submitted (see discussion).

## Carcinogenicity

Table 3: 6-month carcinogenicity study with venetoclax and M27

| Report number/GLP /Duration   | Species/Sex/ Number/Group                                                                  | Dose (mg/kg/day)/ Route                                                                                                          |
|-------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| R&D/18/0248 GLP 6-months      | Tg-rasH2 transgenic mice (Mouse Taconic Model 001178- T(hemizygous), CByB6F1-Tg(HRAS)2Jic) | 0 (control), Venetoclax: 0, 40, 130, 400 M27: 250 N-nitroso-N-methylurea (MNU) (positive control): 75 single dose IP Oral gavage |
|                               | 25/sex/group 18/sex/group TK (non- transgenic littermates)                                 | Control item 1: Water+ 0,1% antifoam Control item 2: Milled placebo                                                              |

Mortality: Incidence of unscheduled deaths was similar in control or test item groups (≤2 animals/sex/group). In the positive control group 0/15 males and 6/15 females died early. The deaths in positive control females were attributed to tumours of the skin, lymphoid tissue, lung and uterus.

Survival (%):

Control item 1: 96 males, 96 females

Control item 2: 100 males, 100 females

Venetoclax 40mg/kg/day: 92 males, 92 females

Venetoclax 130mg/kg/day: 92 males, 100 females

Venetoclax 400mg/kg/day: 96 males, 100 females

M27 250mg/kg/day: 96 males, 92 females

MNU 75mg single dose: 100 males, 60 females

<div style=\"page-break-after: always\"></div>

Clinical signs: Venetoclax: ≥40mg/kg/day; Hair discoloured grey/white in all animals at all doses. M27: Hair discoloured grey in 1 female.

Body weight, food consumption: All groups gained body weight, but females given venetoclax gained less weight (5-8%) than controls. No significant differences in food consumption were found.

Macroscopic pathology: Venetoclax 400mg/kg/day; Slight increased incidence of glandular stomach swollen/thickened in females.

Histopathology:

Neoplastic lesions: none

Non-neoplastic lesions: Venetoclax ≥40mg/kg/day ; Generalised decrease in lymphocytes in Gut associated lymphoid tissue (GALT), lymph nodes, thymus and spleen, increased extramedullary haematopoiesis in spleen, and liver vacuolation (in males only). Venetoclax 400mg/kg/day; Inflammation and hyperplasia of the glandular stomach (in males only).

M27 250mg/kg/day: Liver vacuolation (in males only), Decrease in lymphocytes in lymph nodes, spleen and thymus.

Table 4: Summary of toxicokinetics for venetoclax and M27

| Daily dose (mg/kg/day)       | 40 (ven) males   | 130 (ven) males   | 400 (ven) males   | 250 (M27) males   | 40 (ven) females   | 130 (ven) females   | 400 (ven) females   | 250 (M27) females   |
|------------------------------|------------------|-------------------|-------------------|-------------------|--------------------|---------------------|---------------------|---------------------|
| Number of TK animals         | 18               | 18                | 18                | 18                | 18                 | 18                  | 18                  | 18                  |
| Day 91: Mean C max (µg/mL)   | 2,58             | 3,48              | 5,44              | 8,35              | 2,97               | 4,12                | 6,45                | 13,6                |
| Day 91: Mean AUC (µg •hr/mL) | 20,6             | 34,8              | 52,4              | 64,7              | 20,4               | 37,2                | 77,8                | 103                 |

| Daily dose M27 (mg/kg/day)   | 30 males   | 100 males   | 300 males   | 30 females   | 100 females   | 300 females   |
|------------------------------|------------|-------------|-------------|--------------|---------------|---------------|
| Number of TK animals         | 9          | 9           | 9           | 9            | 9             | 9             |
| Day 1: Mean C max (µg/mL)    | 1,34       | 3,7         | 7,57        | 3,13         | 9,02          | 24,6          |
| Day 1: Mean AUC (µg •hr/mL)  | 8,81       | 28          | 62,2        | 19,2         | 65,6          | 179           |
| Day 28: Mean C max (µg/mL)   | 1,37       | 3,23        | 12,1        | 2,79         | 7,46          | 25,2          |
| Day 28: Mean AUC (µg •hr/mL) | 7,26       | 24,5        | 88,7        | 15,5         | 54,8          | 271           |

## Reproduction toxicity

The applicant has conducted two new EFD studies (one DRF and one pivotal GLP study) to evaluate the potential of embryo-foetal toxicity of the major human metabolite M27. Both studies were performed in CD1-mice and are summarised below.

Table 5: Embryo-Foetal DRF study

| Study ID /GLP/ Duration                  | Species/Sex/ Number/Group                                                                        | Dose (mg/kg/day)                                                                                                   | NOAEL (mg/kg/day)                 |
|------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| R&D18/0477 DRF, Non-GLP Treatment GD6-15 | Mouse Crl:CD1 Pregnant dams Age: ~11w of age. 10 females/group 3-15 pregnant females used for TK | 0 (Control) M27: 30, 100, 250 Dose volume: 10 mL/kg/dose Control: copovidone in 0,1% antifoam C in purified water. | F 0 females: 250 F 1 litters: 250 |

<div style=\"page-break-after: always\"></div>

Maternal mortality: One mouse in the 100mg/kg/day dose group was euthanised on GD10 due to adverse clinical signs (decreased activity, hunched posture, cold to touch and abnormal breathing sounds). This mouse lost 10% of body weight from GD9 to GD10. At necropsy the mouse had a perforation in the trachea and the applicant considered this unscheduled death to be unrelated to treatment and due to gavage error.

One mouse receiving 30mg/kg/day was euthanised on GD11 due to adverse clinical signs (decreased activity, cold to touch, swollen forelimbs and thorax, erected fur and eye discharge). This mouse lost 19% of body weight from GD9 to GD11. At necropsy the mouse had a perforation in the esophagus and accumulation of gritty, tan material in the right axilla and the applicant considered this unscheduled death to be unrelated to treatment and due to gavage error.

## Maternal performance: No M27 related effects detected

Litters: The number of late resorptions was increased in the 250mg/kg/day dose group compared to control (0,3 resorptions/litter vs 0,0 in controls).  This increase was considered to be unrelated to the treatment because the incidence was within the historical range of the testing facility.

## Toxicokinetics

| Toxicokinetics on GD 15   | Toxicokinetics on GD 15   | Toxicokinetics on GD 15   | Toxicokinetics on GD 15   | Toxicokinetics on GD 15   |
|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| M27 Dose (mg/kg/day)      | Cohort                    | Cmax (µg/mL)              | Tmax (h)                  | AUC (µg •hr/mL)           |
| 30                        | Maternal                  | 8,66                      | 3,0                       | 40,1                      |
| 30                        | Foetal                    | 0,60                      | 6,0                       | 6,72                      |
| 100                       | Maternal                  | 17,0                      | 3,0                       | 121                       |
| 100                       | Foetal                    | 1,13                      | 6,0                       | 15,9                      |
| 250                       | Maternal                  | 20,4                      | 6,0                       | 135                       |
| 250                       | Foetal                    | 1,59                      | 12,0                      | 26,0                      |

## Embryo-foetal GLP study

| Study ID /GLP/ Duration         | Species/Sex/ Number/Group                                                                        | Dose (mg/kg/day)                                                                                              | NOAEL (mg/kg/day)                                                                       |
|---------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| R&D18/0648 GLP Treatment GD6-15 | Mouse Crl:CD1 Pregnant dams Age: ~11w of age. 25 females/group 6-30 pregnant females used for TK | 0 (Control) M27: 30, 250 Dose volume: 10 mL/kg/dose Control: copovidone in 0,1% antifoam C in purified water. | Applicant F 0 females: 250 F 1 litters: 250 Rapporteur F 0 females: 250 F 1 litters: 30 |

Maternal mortality: No mortality or cases of moribund condition leading to termination.

Maternal clinical signs: None reported.

Maternal body weight and food consumption: No effects of M27 on maternal body weight or food consumption. Mean maternal body weight and mean maternal body weight gain for M27 treated animals on GD18 were ~98 % of controls. Mean maternal food consumption was ~106% of controls.

<div style=\"page-break-after: always\"></div>

Table 6: Summary of Maternal performance and litters outcomes

| M27 Dose (mg/kg/day)                            | 0    | 30   | 250   |
|-------------------------------------------------|------|------|-------|
| No. of dams                                     | 25   | 25   | 25    |
| No. of pregnant dams                            | 25   | 25   | 24    |
| Mortality                                       | 0    | 0    | 0     |
| No. aborted or with total resorption of litters | 0    | 0    | 0     |
| Mean no. of Corpora Lutea                       | 15,8 | 15,4 | 17    |
| Mean no. of implantations                       | 15   | 14,6 | 15,2  |
| Mean% preimplantation loss                      | 4,69 | 4,65 | 8,7   |

| M27 Dose (mg/kg/day)                        | 0     | 30    | 250   |
|---------------------------------------------|-------|-------|-------|
| No. of litters evaluated                    | 25    | 25    | 25    |
| Total no. of foetuses examined              | 362   | 336   | 328   |
| Mean total no. of foetuses                  | 14,6  | 13,5  | 13,7  |
| No. of dead foetuses                        | 2     | 2     | 0     |
| Mean no. of resorptions/litter (early)      | 0,3   | 0,9   | 1,2*  |
| Mean no. of resorptions/litter (late)       | 0,1   | 0,2   | 0,3   |
| Mean no. of total resorptions/litter (late) | 0,4   | 1,1   | 1,5*  |
| Mean %postimplantation loss                 | 3     | 7,87  | 9,72* |
| Mean foetal bodyweight (g) (both sexes)     | 1,352 | 1,374 | 1,336 |
| Foetal sex ratios (% males)                 | 51,88 | 48,32 | 47,42 |

<div style=\"page-break-after: always\"></div>

Table 7: Foetal external examination

| Summary of external foetal abnormalities (Incidental or Malformations) Foetuses N (%) Litters N (%)   | Summary of external foetal abnormalities (Incidental or Malformations) Foetuses N (%) Litters N (%)   | Summary of external foetal abnormalities (Incidental or Malformations) Foetuses N (%) Litters N (%)   | Summary of external foetal abnormalities (Incidental or Malformations) Foetuses N (%) Litters N (%)   |
|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| M27 Dose (mg/kg/day)                                                                                  | 0                                                                                                     | 30                                                                                                    | 250                                                                                                   |
| No. of foetuses examined                                                                              | 362                                                                                                   | 336                                                                                                   | 328                                                                                                   |
| Eye, open                                                                                             | 1 (0,27) 1 (4,0)                                                                                      | 0 (0) 0 (0)                                                                                           | 3 (0,74) 1 (4,2)                                                                                      |
| Cleft palate                                                                                          | 1 (0,27) 1 (4,0)                                                                                      | 2 (0,56) 2 (8,0)                                                                                      | 0 (0) 0 (0)                                                                                           |
| Head/neck exencephaly                                                                                 | 1 (0,27) 1 (4,0)                                                                                      | 0 (0) 0 (0)                                                                                           | 0 (0) 0 (0)                                                                                           |
| Hindlimb malrotated                                                                                   | 1 (0,24) 1 (4,0)                                                                                      | 0 (0) 0 (0)                                                                                           | 2 (0,61) 2 (8,3)                                                                                      |
| Hindpaw, hyperflexion                                                                                 | 0 (0) 0 (0)                                                                                           | 0 (0) 0 (0)                                                                                           | 1 (0,28) 1 (4,2)                                                                                      |
| Tail, bent                                                                                            | 0 (0) 0 (0)                                                                                           | 2 (0,50) 2 (8,0)                                                                                      | 0 (0) 0 (0)                                                                                           |

Table 8: Foetal visceral and skeletal examination

| Summary of visceral foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%) Litters N (%)   | Summary of visceral foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%) Litters N (%)   | Summary of visceral foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%) Litters N (%)   | Summary of visceral foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%) Litters N (%)   |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| M27 Dose (mg/kg/day)                                                                                              | 0                                                                                                                 | 30                                                                                                                | 250                                                                                                               |
| No. of foetuses examined                                                                                          | 175                                                                                                               | 162                                                                                                               | 159                                                                                                               |
|                                                                                                                   | 0 (0) 0 (0)                                                                                                       | 1 (0,67) 1 (4,0)                                                                                                  | 0 (0) 0 (0)                                                                                                       |
| Diaphragm, hernia                                                                                                 |                                                                                                                   |                                                                                                                   |                                                                                                                   |
| Eye, lens discoloured                                                                                             | 2 (1,14) 2 (8,0)                                                                                                  | 0 (0) 0 (0)                                                                                                       | 2 (1,39) 1 (8,3)                                                                                                  |
| Eye, retina fold                                                                                                  | 1 (0,57)                                                                                                          | 0 (0)                                                                                                             | 2 (1,39)                                                                                                          |
|                                                                                                                   | 1 (4,0)                                                                                                           | 0 (0)                                                                                                             | 1 (4,2)                                                                                                           |
| Kidney, absent                                                                                                    | 0 (0)                                                                                                             | 1 (0,57)                                                                                                          | 0 (0)                                                                                                             |
|                                                                                                                   | 0 (0)                                                                                                             | 1 (4,0)                                                                                                           | 0 (0)                                                                                                             |
| Liver, lobe                                                                                                       | 0 (0)                                                                                                             | 1 (0,67)                                                                                                          | 0 (0)                                                                                                             |
| malpositioned                                                                                                     | 0 (0)                                                                                                             | 1 (4,0)                                                                                                           | 0 (0)                                                                                                             |
| Lung, small                                                                                                       | 0 (0)                                                                                                             | 1 (0,67)                                                                                                          | 0 (0)                                                                                                             |
|                                                                                                                   | 0 (0)                                                                                                             | 1 (4,0)                                                                                                           | 0 (0)                                                                                                             |
| Cleft palate                                                                                                      | 0 (0)                                                                                                             | 2 (1,11)                                                                                                          | 0 (0)                                                                                                             |
|                                                                                                                   | 0 (0)                                                                                                             | 2 (8,0)                                                                                                           | 0 (0)                                                                                                             |
| Ureter, absent                                                                                                    | 0 (0)                                                                                                             | 1 (0,57)                                                                                                          | 0 (0)                                                                                                             |
|                                                                                                                   | 0 (0)                                                                                                             | 1 (4,0)                                                                                                           | 0 (0)                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Summary of skeletal foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%)   | Summary of skeletal foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%)   | Summary of skeletal foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%)   | Summary of skeletal foetal abnormalities (Incidental, Malformations or Variations) Foetuses N (%)   |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| M27 Dose (mg/kg/day)                                                                                | 0                                                                                                   | 30                                                                                                  | 250                                                                                                 |
| No. of foetuses examined                                                                            | 187                                                                                                 | 174                                                                                                 | 169                                                                                                 |
| Skeletal mechanical damage                                                                          | 3 (1,71) 2 (8,0)                                                                                    | 6 (3,90) 3 (12,0)                                                                                   | 12 (8,66) 7 (29,2)                                                                                  |
| Skull, frontal misshapen                                                                            | 1 (0,50) 1(4,0)                                                                                     | 0 (0) 0 (0)                                                                                         | 0 (0) 0 (0)                                                                                         |
| Skull, palatine cleft                                                                               | 1 (0,50) 1 (4,0)                                                                                    | 0 (0) 0 (0)                                                                                         | 0 (0) 0 (0)                                                                                         |
| Skull , parietal misshapen                                                                          | 1 (0,50) 1 (4,0)                                                                                    | 0 (0) 0 (0)                                                                                         | 0 (0) 0 (0)                                                                                         |
| Skull, supraoccipital absent                                                                        | 1 (0,50) 1 (4,0)                                                                                    | 0 (0) 0 (0)                                                                                         | 0 (0) 0 (0)                                                                                         |
| Skull, suture bone present                                                                          | 34 (18,1) 14 (56,0)                                                                                 | 33 (20,1) 15 (60,0)                                                                                 | 33 (19,5) 19 (79,2)                                                                                 |
| Skull , zygoatic arch incomplete ossification                                                       | 0 (0) 0 (0)                                                                                         | 0 (0) 0 (0)                                                                                         | 1(0,69) 1 (4,2)                                                                                     |
| Sternebra, asymmetric                                                                               | 6 (3,3) 5 (20,0)                                                                                    | 3 (1,81) 2 (8,0)                                                                                    | 0 (0) 0 (0)                                                                                         |
| Sternebra , bipartite ossification                                                                  | 4 (2,29) 3 (12,0)                                                                                   | 2 (1,24) 2 (8,0)                                                                                    | 0 (0) 0 (0)                                                                                         |
| Sternebra, fused Sternebra                                                                          | 2 (1,02) 2 (8,0) 1 (0,57)                                                                           | 1 (0,57) 1 (4,0) 1 (0,57)                                                                           | 0 (0) 0 (0) 0 (0)                                                                                   |
| Sternebra misshapen                                                                                 | 2 (1,14) 2 (8,0)                                                                                    | 1 (0,57) 1 (4,0)                                                                                    | 0 (0) 0 (0)                                                                                         |
| Supernumerary rib , cervical short                                                                  | 46 (23,72) 17 (68,0)                                                                                | 21 (12,16) 14 (56,0)                                                                                | 28 (15,5) 13 (54,2)                                                                                 |
| Vertebra, Cervical arch incomplete ossification                                                     | 3 (1,52) 3 (12,0)                                                                                   | 3 (1,72) 1 (4,0)                                                                                    | 1 (0,52) 1 (4,2)                                                                                    |

Foetal ossification site averages

There were no statistically significant or biologically important differences compared to control in the average numbers of ossification sites per foetus for the hyoid, vertebrae, ribs, sternum, forelimbs or hindlimbs.

## Table 9: Toxicokinetics

| Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   | Mean toxicokinetic parameters for M27 in maternal mouse plasma   |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
|                                                                  | GD6                                                              | GD6                                                              | GD6                                                              | GD15                                                             | GD15                                                             | GD15                                                             |
| Dose (mg/kg/day)                                                 | Cmax (µg/mL)                                                     | Tmax (hr)                                                        | AUC (µg •hr/mL)                                                  | Cmax (µg/mL)                                                     | Tmax (hr)                                                        | AUC (µg •hr/mL)                                                  |
| 30                                                               | 2,77                                                             | 3,0                                                              | 14,8                                                             | 5,71                                                             | 3,0                                                              | 35,2                                                             |
| 250                                                              | 13,7                                                             | 3,0                                                              | 75,3                                                             | 14,7                                                             | 3,0                                                              | 131                                                              |

<div style=\"page-break-after: always\"></div>

| Mean M27 ratios of foetal to maternal AUC   | Mean M27 ratios of foetal to maternal AUC   | Mean M27 ratios of foetal to maternal AUC   | Mean M27 ratios of foetal to maternal AUC   |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Dose (mg/kg/day)                            | GD15 Foetal (µg/mL)                         | Maternal (µg/mL)                            | AUC ratio (Foetal/Maternal)                 |
| 30                                          | 14,0                                        | 35,2                                        | 0,398                                       |
| 250                                         | 70                                          | 131                                         | 0,534                                       |

## Toxicokinetic data

Toxicokinetic data are presented in the description of the individual studies.

## Local tolerance

No new local tolerance studies have been submitted (see discussion).

## Other toxicity studies

The applicant has provided juvenile toxicity study for venetoclax performed in mice, however since this variation application only concerns only adult population, the juvenile toxicity study has not been assessed within this application.

## 2.2.4. Ecotoxicity/environmental risk assessment

The applicant has provided an updated ERA dated March 2019. Only the new information and its consequences have been considered in this assessment.

In the Phase I assessment, the Predicted Environmental Concentration (PEC) for PECSURFACEWATER was calculated with the FpenACTUAL value of 0.00048 (0.048%) as reported by Orphanet. The resulting PEC of 0.096 μ g/L exceeded the action limit of 0.01 μ g/L, triggering a Phase II assessment. Persistence, bioaccumulation, and toxicity (PBT) were assessed in Phase II Tiers A and B.

A Phase II Tier A base set of fate and effect studies was conducted with the exception of ready biodegradability (OECD 301). The PECSURFACEWATER of 0.000096 mg/L (0.096 μ g/L) was used to develop the PEC/Predicted No Effect Concentration (PNEC) ratios. All the Phase II Tier A PEC/PNEC ratios were &lt; 1.

Table 10: Summary  of PEC/PNEC ratio and outcome

| Endpoint       | PEC/PNEC (mg/L)   | PEC/PNEC value   | PEC/PNEC evaluation   | Outcome                      |
|----------------|-------------------|------------------|-----------------------|------------------------------|
| Water          | 0,000096/0,00073  | 0,13             | <1                    | No further testing necessary |
| Groundwater    | 0,000024/0,00073  | 0,033            | <1                    | No further testing necessary |
| Microorganisms | 0,000096/100      | 0,00000096       | <0,1                  | No further testing necessary |
| Sediment       | 0,29/5,56         | 0,052            | <1                    | No further testing necessary |
| Soil           | 0,0308/17,9       | 0,0017           | <1                    | No further testing necessary |

<div style=\"page-break-after: always\"></div>

## 2.2.5. Discussion on non-clinical aspects

The present procedure concerns a grouped type II variation application to extend the approved indication of venclyxto (venetoclax) in combination with the anti -CD20 antibody obinutuzumab, as frontline treatment of CLL. Since the new proposed indication does not fall within the scope of ICH S9, the applicant has performed new non-clinical studies. The choice of studies were endorsed in a scientific advice provided in 2017 by the CHMP (EMA/CHMP/SAWP/716506/2017) and include: a 6 monthtransgenic mouse carcinogenicity study, which includes dosing of venetoclax and the human metabolite M27; a 4-week mouse repeat-dose toxicity study with M27 and; two mouse embryo-foetal development (EFD) studies with M27.  All studies were performed in mice which is considered to be a relevant species.

## 4-week repeat-dose toxicity study (R&amp;D/16/0143) with M27 in mice

The M27 human metabolite is similar to venetoclax in structure but has notably less potency (approx. 170-fold less). M27 is observed at exposures greater than 10% of total venetoclax related exposures and at significantly greater levels in humans than the maximum exposure seen in animals. M27 represents up to around 30% of venetoclax+M27 exposure at steady state. By contrast, steady state plasma levels of M27 in mice and dogs were ≤ 5% of human exposure. M27 is thought to be formed via mono -oxidation of venetoclax on the 6-position of the cyclohexenyl moiety to give M5, followed by enzyme-mediated cyclization at the α -carbon of piperazine. For testing purposes, M27 (A-1621332) was synthetized.

In a 4-week repeat-dose toxicity study, mice (wild-type rasH2 mice) were dosed orally with synthesised M27 up to doses of 300mg/kg/day. Plasma (AUC) exposures to M27 at and above those at the venetoclax maximum recommended human dose (400mg/day) were achieved.

All mice survived throughout the study and no adverse findings were reported. Similar to venetoclax, M27 exposure resulted in haematological toxicity manifested by a decrease in lymphocyte count and haemoglobin.

There were no M27-related clinical observations and no M27-related changes in clinical chemistry, organ weight, gross- or histopathology.

A minimal non-dose related decrease in food intake was recorded in males but not in females. The decrease in food intake was coupled to a decrease in percent mean body weight gain in males at 30 and 300mg/kg/day but not at 100mg/kg/day. However, since the differences in the absolute mean body weight gain can be considered small (0,35g and 0,23g vs 0,55g in controls) and there was no correlation with mean body weight and food consumption, the relevance of this finding is uncertain.

A 6-month carcinogenicity study of venetoclax and M27 in transgenic mice evaluated the carcinogenicity of venetoclax and the major human metabolite M27 (synthesized and dosed) in orally administered TgrasH2 transgenic mice. The top dose of venetoclax (400mg/kg/day) and M27 (250mg/kg/day) was the maximum feasible dose (based on dose volume and viscosity limitations) and resulted in an exposure margin to clinical AUC of around 2-fold for venetoclax and 5,8-fold for M27. Venetoclax and the M27 major human metabolite were not carcinogenic in this study at oral doses up to 400 mg/kg/day of venetoclax and at a single dose level of 250 mg/kg/day of M27.

As observed in previous repeat-dose studies performed in CD1 mice prior the initial MAA, non-neoplastic microscopical  findings related to venetoclax were seen in the lymphoid system (GALT, lymph nodes and thymus) and spleen in both sexes and included a generalised decrease in lymphocytes and increased extramedullary haematopoiesis in the spleen. In general, similar but lower incidence/severity of venetoclax-related changes in the lymphoid system and liver were present in mice given M27 at 250mg/kg/day, consistent with the weaker pharmacologic potency of M27 as a Bcl-2 inhibitor.

<div style=\"page-break-after: always\"></div>

The MAH's rationale for not performing a 2-year rat study, has been accepted in the CHMP scientific advice EMA/CHMP/SAWP/716506/2017 and the rationale is based on results obtained from a 13-week GLP dose-selection study in rat in which decreases in haemoglobin and RBC levels were observed. In the rat study there were toxic effects in female rats resulting in moribundity and early termination at high dose (400mg/kg/day) and adverse decreases in RBC mass at 150 mg/kg/day, corresponding to clinical exposure. The MTD in females was set to 8mg/kg/day. Although not as pronounced, similar effects were observed in male rats were a more than 10% decrease in body weight gain resulted in an MTD of 150mg/kg/day, corresponding to an exposure margin of 0,8x to clinical exposure. These results indicate that even at sub-therapeutic exposure levels, female rats would not survive for 2-years and the survival of male rats would be uncertain and therefore omission of the 2-year rat study is acceptable.

In conclusion, the absence of carcinogenic effects of venetoclax or M27 in the 6-month transgenic mouse carcinogenicity study, in combination with previously reported negative genotoxicity findings with venetoclax and M27 and the absence of neoplastic lesions in chronic venetoclax toxicity studies in CD1 mice (6-months) and dogs (9-months), suggest a low carcinogenic risk to patients treated with venetoclax.

In the Embryo-foetal studies study performed for the initial MAA, venetoclax was associated with postimplantation loss and decreased foetal body weight in mice and maternal toxicity in rabbits. Only one species (mouse) was used to assess for M27-related maternal and embryo-foetal toxicity. The approach was considered acceptable in the CHMP scientific advice (EMA/CHMP/SAWP/716506/2017).

The applicant performed two new EFD studies (one DRF and one pivotal GLP study), both performed in CD1 mice, with the major human metabolite M27.  In the pivotal GLP study the high dose of 250 mg/kg/day (dosed from GD6 to GD15) was the maximum feasible dose (based on dose volume and viscosity limitations) and resulted in an exposure margin of maternal to clinical AUC of around 8-fold and a mean foetal to maternal M27 concentration ratio of 0,534.

The major human metabolite M27 was associated with post-implantation loss and resorptions at exposures approximately 9-times the human M27-AUC exposure at a 400 mg dose of venetoclax. In rabbits, venetoclax produced maternal toxicity, but no foetal toxicity at exposures of 0.1 times the human AUC exposure at a 400 mg dose.

There were no mortalities at any doses tested. Compared to the concurrent controls, there were signs of M27-related adverse effects on embryo-foetal development, based on the increase in resorptions (control:0,4; 30mg:1,1; 250mg:1,5) and post-implantation losses (control:3%; 30mg:7,87%; 250mg: 9,72%). The proposed maternal NOAEL of 250mg/kg/day is agreed. The wording the SmPC section 4.6 where use of venetoclax is not recommended during pregnancy and breast-feeding remains unchanged.

The applicant has provided juvenile toxicity study for venetoclax performed in mice, however since this variation application only concerns only adult population, the juvenile toxicity study has not been assessed within this application.

## Ecotoxicity/environmental risk assessment

Due to the change in indication, the applicant has provided an updated ERA based on new Fpen value (0,48%) which has been taken from the Orphanet portal for rare diseases. This approach is considered acceptable. PEC/PNEC ratio values were all &lt;1. In line with previous assessment of venetoclax and based on the updated data submitted in this application, the new indication does not lead to a significant increase in environmental exposure further to the use of venetoclax.

<div style=\"page-break-after: always\"></div>

## 2.2.6. Conclusion on the non-clinical aspects

The non-clinical aspects in support of this extension of indication are adequately studied. The new nonclinical studies assessed in this application do not indicate an increased risk of carcinogenicity of either venetoclax or the M27 major human metabolite. M27 produced embryo-foetal toxicity at exposures approximately 8-times the human margins.

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of venetoclax.

Considering the above data, venetoclax is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## Tabular overview of clinical studies

<!-- image -->

## 2.3.2. Pharmacokinetics

The new clinical pharmacology information includes venetoclax PK, efficacy, and safety data from patients with 1L and R/R CLL participating in the following two clinical studies:

- Pivotal Phase III Study BO25323, is an ongoing trial evaluating the efficacy and safety of venetoclax + obinutuzumab (VEN+G), Arm A compared with obinutuzumab + chlorambucil

<div style=\"page-break-after: always\"></div>

(GClb), Arm B in patients with previously untreated CLL patients and coexisting medical conditions.  The study included:  pre- and 4 hours post-dose PK sampling for venetoclax, pre- and end of infusion PK sampling for obinutuzumab (approximately four PK samples per VEN+G treated patient) on a single visit of Day 1 in Cycle 4 from 194 patients in Arm A.  A summary of PK concentrations for venetoclax and obinutuzumab from the primary CSR are provided in this document.  A PopPK analysis of the venetoclax PK data using a Bayesian approach and the E-R (efficacy/safety/tolerability) analysis for patients randomized to VEN+G arm was performed.

- Updated data from the supportive Phase Ib Study GP28331, which is an ongoing Phase Ib, multicenter, open-label, dose-finding and safety study of venetoclax administered in combination with obinutuzumab.  A total of 82 patients were enrolled in the study, 50 R/R and 32 previously untreated CLL patients. This study is a dose-escalation study with venetoclax doses ranging from 100 mg to 400mg.  The study includes venetoclax and obinutuzumab PK sampling from 81 patients and was included in the original submission. The venetoclax PK data from this study was also included in the PopPK analysis.

## Analytical Methods

Details of specific and sensitive bioanalytical assays using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) developed and validated for the quantitative determination of venetoclax in human plasma were provided in the original application.

During sample analysis, the assay reproducibility was demonstrated at least once per assay using an incurred samples reanalysis (ISR) approach.  There was no change in analytical methods for venetoclax assays that were provided in the original application and subsequent filings.

Details of the specific and sensitive bioanalytical assays for the quantitation of obinutuzumab using an enzyme-linked immunosorbent assay (ELISA) platform validated at PPD and a titer-based bridging ELISA for the quantitation of anti-obinutuzumab antibodies developed at PPD were provided to the agency during the registration of Gazyva ® .  The method validations were conducted in compliance with internal standard operating procedures.  The assay reproducibility for the quantitation of obinutuzumab was demonstrated using an ISR approach during sample analysis.

Table 11 . Summary of Bioanalytical Methods for Quantitation of Venetoclax and Obinutuzumab

|                          |                   |              |                     | Inter-Run      | Inter-Run     |                                |        |
|--------------------------|-------------------|--------------|---------------------|----------------|---------------|--------------------------------|--------|
| Compound                 | Method (Matrix)   | LLOQ         | Assay Range         | Accuracy %Bias | Precision %CV | Long Term Stability            | ISR    |
| Venetoclax (A-1195425)   | LC-MS/MS (plasma) | 2.05 ng/mL   | 2.05 to 2050 ng/mL  | -1.5 to 3.7    | 1.6 to 3.2    | 1500 d (~-20°C) 210 d (~-70°C) | passed |
|                          |                   | 2.11 ng/mL   | 2.11 to 2030 ng/mL  | -1.6 to 0.0    | 1.6 to 5.5    |                                |        |
| Obinutuzumab (RO5072759) | ELISA (serum)     | 4.05 ng/mL a | 4.05 to 400 ng/mL a | -2.72 to 3.58  | 3.55 to 12.4  | 1126 d (~-25°C and ~-80°C)     | passed |

LLOQ = Lower limit of quantitation; CV = Coefficient of variation; ISR = Incurred samples reanalysis; LC-MS/MS = Liquid chromatography tandem mass spectrometry; ELISA = Enzyme-linked immunosorbent assay; d = Day

- a. Concentration in 100% serum (Minimum Required Dilution (MRD) 1:10).

<div style=\"page-break-after: always\"></div>

Table 12. Summary of Bioanalytical Method for Detection of Anti-Drug Antibodies (AntiObinutuzumab Antibodies)

| Method (Matrix)   | MRD   | Sensitivity   | Drug Tolerance                                  | Intra-Run Precision %CV   | Inter-Run Precision %CV   | Selectivity                                                         |
|-------------------|-------|---------------|-------------------------------------------------|---------------------------|---------------------------|---------------------------------------------------------------------|
| ELISA (serum)     | 1:10  | 18.4 ng/mL    | 500 ng/mL PC detected in presence of 47.8 µg/mL | 1.88 to 4.87              | 10.9 to 18.7              | 100% of LPC samples above CP were within < 100% of Control response |

MRD = Minimum required dilution; CV = Coefficient of variation; ELISA = Enzyme-linked immunosorbent assay; PC = Positive control; LPC = Low positive control; CP = Cut point

## Pharmacokinetics

## Population PK

## Methods

The PopPK of venetoclax in R/R CLL/SLL, NHL, and healthy subjects was characterized in support of the filing of venetoclax used as monotherapy in patients with R/R CLL. The current PopPK analysis used the PopPK model structure (a two-compartment PK model with first-order absorption and elimination) from the initial MAA with the parameters implemented as informative Bayesian priors. This model was then fit to the Studies GP28331 and BO25323 PK data to yield the final PopPK model and parameters.

Model parameters were estimated with the new data, and additional covariates (not previously evaluated) were tested in the model. These covariates were obinutuzumab co-administration and Binet stage. Bayesian prior distributions were not used for these additional covariates.  Covariate effects were added to the model multiplicatively and tested with alpha=0.01 significance level.  The final model was evaluated using diagnostic plots, visual predictive check, and normalized prediction distribution errors (NPDE) plots.  Correlations of apparent clearance with previously tested covariates (that were found not to be significant in the previous model) and the additional covariates (not previously evaluated) were investigated by diagnostic plots. Individual post-hoc estimated PK parameters were computed from the final model and used to calculate steady state exposures.  These PK parameters and exposures were summarized overall and stratified by study.  The non-linear mixed-effects modelling software, NONMEM Version 7.4.3, utilizing PRIOR subroutine and the first-order conditional estimation method with interaction was used for the analysis.

## Results

Among 216 patients randomized to Arm A in study BO25323, 13 patients in the safety run-in phase from Study BO25323, and 82 patients enrolled in Study GP28331, a total of 274 patients (194 from Study BO25323 and 80 from Study GP28331) had at least one quantifiable PK sample and were included in the analysis.  A total of 1,563 quantifiable samples from 274 patients were used in the analysis. A total of 2.6% of samples were below limit of quantification and were excluded from the analysis.

The final model was structurally identical to the model of the previous analysis. The data were described by the two-compartment popPK model with first-order absorption and elimination.  The parameter estimates were very similar to the estimates of the previous analysis.

<div style=\"page-break-after: always\"></div>

Table 13. Parameter Estimates for the Final Model

| Parameter         | Parameter         | Estimate          | RSE(%)            | 95%CI              |                   |                   |
|-------------------|-------------------|-------------------|-------------------|--------------------|-------------------|-------------------|
| CL/F (L/day)      | θ                 | 446               | 2.48              | 425 - 468          |                   |                   |
| V2/F (L)          | θ2                | 116               | 13.2              | 86.2 - 146         |                   |                   |
| Q/F (L/day)       | θ3                | 98.8              | 4.95              | 89.1-108           |                   |                   |
| V3/F (L)          |                   | 121               | 3.74              | 112 - 130          |                   |                   |
| Ka                | θs                | 3.76              | 3.76              | 3.48 - 4.04        |                   |                   |
| F1,tasting        | 6                 | 0.338             | 0.952             | 0.332-0.344        |                   |                   |
| F1,moderate fat   |                   | 1.4               | 8.00              | 1.18 - 1.62        |                   |                   |
| F1.nigh fat       |                   | 1.44              | 1.28              | 1.41 - 1.48        |                   |                   |
| F1,ted            |                   | 1.29              | 3.85              | 1.19 - 1.39        |                   |                   |
| F1.DOSE           | θ10               | -0.150            | 2.16              | -0.157 - -0.144    |                   |                   |
| CLRTX             | 11                | 1.24              | 2.90              | 1.17 - 1.32        |                   |                   |
| CLC3AHIB=2        | θ12               | 0.861             | 4.08              | 0.793-0.930        |                   |                   |
| CLC3AHIB=3        | 013               | 0.178             | 5.95              | 0.157 - 0.199      |                   |                   |
| V2,PTOP>0         | 014               | 1.73              | 12.0              | 1.33 - 2.14        |                   |                   |
| V2,SEX=1          | 015               | 0.703             | 5.65              | 0.625 - 0.781      |                   |                   |
| CLOATP1B3         | θ16               | 0.864             | 2.41              | 0.823-0.905        |                   |                   |
| Parameter         | Parameter         | Estimate          | RSE(%)            | RSE(%)             | Variability       | Shrinkage         |
| W²CL              | Q(1,1)            | 0.164             | 7.85              | 0.139 -0.189       | CV=40.5%          | 21.3%             |
| w²vV2             | Q(2,2)            | 0.153             | 6.11              | 0.135 - 0.171      | CV=39.1%          | 53.4%             |
| W2F1              | Q(3,3)            | 0.0834            | 12.6              | 0.0628 -0.104      | CV=28.9%          | 46.8%             |
| o²prop            | E(1,1)            | 0.222             | 1.47              | 0.216 - 0.229      | CV=47.1%          | 9.5%              |
| O2add             | ∑(2,2)            | 3.03-10-7         | 39.5              | 6.88·10--5.38.10-7 | SD=5.51-10-4      | 9.5%              |
| Derivedparameters | Derivedparameters | Derivedparameters | Derivedparameters | Derivedparameters  | Derivedparameters | Derivedparameters |
| t/2 (day)         |                   | 1.08              |                   |                    |                   |                   |

SE:StandardError:RSE:RelativeStandardError,%RSE=100-SE/PE,wherePEisaparameter estimate;.95%Cl=95%confidenceinterval.SD=StandardDeviation;CV=coefficientof variation, CV=100*SD%.

Table 14. Summary of Conditional Predictions for Model Parameters, Overall and by Study

| Study               | Number of Patients   | F1                | CL/F (L/day)      | V2/F (L)          | CL/F/F1 (L/day)   | tu2 (day)         |
|---------------------|----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                     |                      | GeometricMean(Cv) | GeometricMean(Cv) | GeometricMean(Cv) | GeometricMean(Cv) | GeometricMean(Cv) |
| Allpatients         | 274                  | 0.993 (0.154)     | 443 (0.32)        | 182 (0.241)       | 447 (0.44)        | 1.13 (0.119)      |
| StudyBO25323(CLL14) | 194                  | 0.976 (0.139)     | 458 (0.308)       | 183 (0.204)       | 469 (0.43)        | 1.12 (0.102)      |
| StudyGP28331        | 80                   | 1.03 (0.179)      | 411 (0.336)       | 180 (0.313)       | 397 (0.446)       | 1.16 (0.15)       |
| Allpatients         | 274                  | 1.00 (0.158)      | 466 (147)         | 187 (45.1)        | 491 (220)         | 1.14 (0.158)      |
| StudyBO25323(CLL14) | 194                  | 0.986 (0.139)     | 480 (151)         | 186 (36.6)        | 514 (229)         | 1.12 (0.126)      |
| Study GP28331       | 80                   | 1.05 (0.19)       | 433 (133)         | 189 (61.3)        | 436 (188)         | 1.18 (0.213)      |

The covariatefactors andpatients'individual randomeffectswereused to computePK parameters ineachgroup,assuming 4o0mg dose.CVwas computed as standard deviation of thelog-transformeddata

<div style=\"page-break-after: always\"></div>

Table 15. Difference in Parameter Estimates between the Previous Model and The Final Model

| Parameter       | Parameter   | PreviousModel Estimate   | FinalModel Estimate   |   PercentDifference |
|-----------------|-------------|--------------------------|-----------------------|---------------------|
| CL/F (L/day)    |             | 447                      | 446                   |                -0.1 |
| V2/F (L)        | θ2          | 118                      | 116                   |                -1.3 |
| Q/F (L/day)     | θ3          | 97.2                     | 98.8                  |                 1.6 |
| V3/F (L)        | 04          | 119                      | 121                   |                 2   |
| Ka              | 05          | 3.72                     | 3.76                  |                 1   |
| F1,tasting      | 06          | 0.335                    | 0.338                 |                 1   |
| F1,moterate fat | 07          | 1.31                     | 1.4                   |                 7.3 |
| F1,nigh fat     |             | 1.43                     | 1.44                  |                 1   |
| F1,fed          | θg          | 1.23                     | 1.29                  |                 5   |
| F1.00SE         | θ10         | -0.18                    | -0.15                 |               -16.7 |
| CLRTX           | θ11         | 1.22                     | 1.24                  |                 1.8 |
| CLC3AHIB=2      | θ12         | 0.842                    | 0.861                 |                 2.3 |
| CLC3AHIB=3      | θ13         | 0.184                    | 0.178                 |                -3.2 |
| V2,PTOP>0       | 014         | 1.71                     | 1.73                  |                 1.4 |
| V2,SEX=1        | θ15         | 0.68                     | 0.703                 |                 3.4 |
| CLOATP183       | θ16         | 0.853                    | 0.864                 |                 1.3 |
| W²CL            | Q(1,1)      | 0.153                    | 0.164                 |                 7.3 |
| w²v2            | Q(2,2)      | 0.205                    | 0.153                 |               -25.5 |
| W²F1            | Q(3,3)      | 0.0972                   | 0.0834                |               -14.2 |
| o²prop          | ∑(1,1)      | 0.223                    | 0.222                 |                -0.2 |
| O²add           | ∑(2,2)      | 3.07-10-07               | 3.03·10-07            |                -1.2 |

SE=Standard Error;RSE=RelativeStandard Error,%RSE=100-SE/PE,wherePEisaparameter estimate;.95%Cl=95%confidence interval,SD=Standard Deviation;CV=coefficient ofvariation, CV=100*SD%.

Source:002\\_vs\\_011.csv

## Analysis of covariates

Obinutuzumab co-administration and Binet stage did not influence venetoclax apparent clearance. In agreement with the previous model, no relationship was observed between venetoclax apparent clearance and body weight, age, sex, mild and moderate hepatic and renal impairment, CrCL, AST, ALT, bilirubin, albumin and co-administration of P-glycoprotein (P-gp) inhibitors or weak CYP3A inhibitors.

<div style=\"page-break-after: always\"></div>

Figure 2. Goodness of Fit for the Final Model: Study BO25323

<!-- image -->

DV:Observedconcentrations;PRED:populationpredictionsofthemodel;IPRED:individual predictionsofthemodel;CWRES:conditional weightedresiduals;TiME:timeafterthefirstdose Thegraysolidy=xory=olinesareincludedforreference.Theboldredlinesarethelowess (localregressionsmoother)trendlines.PlotsofCwRESversustimeafterdoseareshownforthe intervalsof10daysand1.2days,tomagnifythetimeintervalofinterest.

Figure 3. Goodness of Fit for the Final Model: Study GP28331

DV:Observedconcentrations;PRED:populationpredictionsof themodel;IPRED:individual predictionsof themodel;CWRES:conditional weightedresiduals;TIME:timeafterthefirst dose. Thegraysolidy=xory=0linesareincludedforreference.Theboldred linesarethelowess (localregressionsmoother)trend lines.PlotsofCwRESversustimeafterdoseare shownforthe intervalsof10daysand1.2days,tomagnifythetimeintervalof interest.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4. Prediction-corrected Visual Predictive Check, Final Model: Study BO25323 (A) and Study GP28331 (B)

<!-- image -->

Pointsareprediction-corrected venetoclax concentrations plottedversus time after mostrecent venetoclax dose.The lines show median(red),and the 5th and 95th percentiles(blue)of the prediction-corrected venetoclax concentrations.The shadedregions show the 9o% confidence intervalsonthesequantitiesobtainedbysimulations.Thesimulatedvalueswerecomputed from 500 trials with dosing,sampling.and the covariate values of the analysis dataset.

Figure 5. Covariate Effects on (CL/F)/F1 for Final Model

Covariate EffectsonVenetoclax(CL/F)/F1 Reference:4o0mgdosewithlow-fatfood

<!-- image -->

Change inParameterRelative toReferencePatient

Ratioofthetypicalparameterandits95%Clforsubpopulationstothetypicalparameterofa referencepatientisillustrated.Standarderrorsoftheparameterestimateswereusedtocompute confidenceintervals.Forcategoricalcovariatesandforcontinuouscovariateswithaspecific value,pointestimates arerepresentedbyopencircles,and95%Clsarerepresented by horizontalbars.Thehatchedarearepresentstypicalvalue±20%.

inhibitorsaffectedvenetoclaxapparentclearance(CL/F).Foodanddoseaffectedvenetoclax relativebioavailability(F1).TheplotshowseffectsofthesecovariatesonCL/F/Fratioasthis ratiodirectlyaffectsvenetoclaxexposure.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Methods

A Bayesian PopPK approach was used to characterize the PK properties of venetoclax in Studies GP28331 and BO25323 and to provide the individual subject exposure metrics for an assessment of the exposureefficacy, exposure-safety and exposure-tolerability relationships for Study BO25323 only.

## · Analysis of Exposure-Safety and Exposure-Tolerability Relationships

The objectives were to investigate the relationships between venetoclax exposure and

- probability of treatmentemergent Grade ≥ 3 neutropenia;
- probability of treatment-emergent Gr ade ≥ 3 thrombocytopenia;
- probability of treatmentemergent Grade ≥ 3 infections (including opportunistic infections);
- probability of treatment-emergent serious adverse events;
- venetoclax dose intensity;
- obinutuzumab dose intensity.

For each AE type, logistic regression models were implemented to assess correlation of the probability of AE occurrence with venetoclax exposure. Covariate modeling was implemented using the forward selection procedure with α = 0.01 significance level. The evaluated covariat es were: demographics (body weight, sex, age, race), geographic region, and baseline disease characteristics (ECOG score, Binet stage, CLL risk group, presence of B-symptoms, CIRS score, and somatic mutations [17p deletion, 11q deletion, 13q deletion, 12t trisomy, TP53 mutation, IgVH mutation]). The resulting full model was used to evaluate the exposure-response relationship. Significance levels of covariate effects (associated p-values) were also presented. As the main purpose of the analysis was to evaluate the effect of exposure, backward elimination from the full model was not implemented.

Dose intensity (DI) was used to characterize treatment tolerability. Correlations of venetoclax and obinutuzumab DI with CmeanSS,nominal  were explored graphically and were summarized by tertials of CmeanSS,nominal .

## · Analysis of Exposure-Efficacy Relationships

The objectives were to assess the relationships between venetoclax exposure and

- investigator-assessed (INV) progression-free survival (PFS);
- independent review committee (IRC) -assessed PFS

For each endpoint, graphical time-to-event analyses (KM plots) stratified by quartiles or tertials of CmeanSS,nominal and Cox Proportional Hazard (CPH) modelling were conducted. CmeanSS,nominal  was used as a measure of exposure; continuous and categorical (tertials of exposure) variables were tested. Covariate CPH modelling was implemented using the forward selection procedure with α = 0.01 significance level and the same covariates as for the exposure-safety analysis. The resulting full model was used to evaluate the exposure response relationship. Significance levels of covariate effects (associated p-values) were also presented.

## · Data

The exposure-safety and exposure-efficacy analyses were conducted with data collected from patients of Study BO25323/CLL14 randomized to venetoclax + obinutuzumab arm. The data from the safety run-in part of the study were not used.

<div style=\"page-break-after: always\"></div>

The empirical Bayes post-hoc estimates of venetoclax primary PK parameters (apparent clearance [CL/F] and relative bioavailability [F1]) estimated using the final population PK model and the relevant PK covariates for each subject, were used to estimate an individual exposure measure, the nominal venetoclax exposure at steady state (CmeanSS,nominal), as follows:

CmeanSS,nominal = Dnom*F1 /(CL/F)/τ,

where Dnom was the nominal target dose assigned to a patient at randomization (400 mg), and τ was inter-dose interval (1 day). Since the PK model predicted dependence of bioavailability on dose, the nominal dose (Dnom) was used to compute the relative bioavailability parameter for the exposure measures. Values of covariates at the time of the first obinutuzumab dose were used to compute apparent clearance.

For subjects who did not have evaluable PK data and were not included in the population PK analysis, the primary PK parameters were imputed using the population estimates and the individual subject's covariate values.

## Results

The analyses included 203 patients from venetoclax + obinutuzumab arm of the study (excluding safety run-in patients).

## · Exposure-Safety Analyses

A total of 118 (58.1%) patients had a treatmentemergent Grade ≥ 3 neutropenia; 30 (14.8%) patients had treatmentemergent Grade ≥ 3 thrombocytopenia; 39 (19.2%) patients had treatment -emergent Grade ≥ 3 Infections, and 96 (47.3%) patients had treatment -emergent serious adverse events. For all investigated types of AE, there were no statistically significant relationships between venetoclax exposure and the probability of AE occurrence.

The logistic regression analysis of exposure-safety relationships in patients from StudyBO25323 indicated that there was no statistically significant relationship between venetoclax exposure and the probability of developing TEAEs of Grade ≥ 3 neutropenia, Grade ≥ 3 thrombocytopenia, Grade ≥ 3 infections or SAEs.

<div style=\"page-break-after: always\"></div>

Figure 6 . Logistic Regression for Grade ≥3 Neutropenia (A), Grade ≥3 Thrombocytopenia (B), Gra de ≥3 Infections (C), Serious Adverse Events (D)

<!-- image -->

The red solid line and green shaded area represent the logistic regression model prediction and 90% confidenceintervalofpredictions.Pointsshowexposureofindividualpatientswithevents(p=1)and withoutevents(p=O).Blacksquaresandverticalgreenlinesshowobservedfractionofsubjectswith events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups. Blue line and point indicate point estimate and 95% coverage interval of steady-stateexposurefollowing 400mg QD doses.P-value isprovided byglm0function.

Subjects with ECOG score ≥ 2 were estimated to have significantly lower probability of Grade ≥ 3 neutropenia (p &lt; 0.01) while subjects with Binet Stage C have significantly higher probability of Grade ≥ 3 neutropenia (p &lt; 0.01). Probability of Grade ≥ 3 neutropenia decreased with increase of baseline bilirubin concentrations (p = 0.012). Subjects with Binet Stage C (BINET =3) were estimated to have significantly higher probability of Grade ≥ 3 thrombocytopenia (p &lt; 0.001). No covariates had significant effects on the probability of Grade ≥ 3 infections at α = 0.01 level. Subjects from Central or Eastern Europe (REGION = 4) were estimated to have a significantly lower probability of serious adverse events (p = 0.006).

<div style=\"page-break-after: always\"></div>

Table 16. Logistic Regression Analyses for Adverse Events:  Final Models

| Parameter                | Estimate                | SE                      | RSE (%)                 | 95%CI                   | P                       |
|--------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Grade≥3Neutropenia       | Grade≥3Neutropenia      | Grade≥3Neutropenia      | Grade≥3Neutropenia      | Grade≥3Neutropenia      | Grade≥3Neutropenia      |
| Intercept                | 0.7538                  | 0.4542                  | 60.25                   | 0.1364;1.644            |                         |
| Slope of CmeansS,nominal | 0.0393                  | 0.3613                  | 919.28                  | -0.6688; 0.7474         | 0.910                   |
| ECOG=2effecta            | -1.278                  | 0.4701                  | 36.79                   | -2.199;-0.3563          | 0.0066                  |
| BINET=3effectb           | 0.9339                  | 0.3231                  | 34.6                    | 0.3006;1.567            | 0.0038                  |
| Bilirubin effect         | -0.9994                 | 0.4001                  | 40.03                   | -1.784;-0.2152          | 0.0120                  |
| Grade≥3Thrombocytopenia  | Grade≥3Thrombocytopenia | Grade≥3Thrombocytopenia | Grade≥3Thrombocytopenia | Grade≥3Thrombocytopenia | Grade≥3Thrombocytopenia |
| Intercept                | 2.127                   | 0.6704                  | 31.52                   | -3.441;-0.8128          |                         |
| Slope of CmeansS.nominal | -0.5497                 | 0.6305                  | 114.7                   | -1.785; 0.6861          | 0.38                    |
| BinetStage=3effectb      | 1.579                   | 0.4441                  | 28.14                   | 0.7081; 2.449           | 0.00038                 |
| SeriousAdverseEvents     | SeriousAdverseEvents    | SeriousAdverseEvents    | SeriousAdverseEvents    | SeriousAdverseEvents    | SeriousAdverseEvents    |
| Intercept                | 0.4833                  | 0.3742                  | 77.43                   | 0.2501; 1.217           |                         |
| Slope of Cmeanss,nominal | -0.3808                 | 0.3674                  | 96.46                   | -1.101; 0.3392          | 0.30                    |
| Region= 4 effect         | -0.9167                 | 0.3364                  | 36.7                    | -1.576;-0.2573          | 0.0064                  |

Estimate:estimateofthecoefficientonamodelparameter;SE=standarderroroftheestimate; RSE=relativestandarderrorof theparameterestimate(%);95%Cl=95%confidenceintervalon theparameterestimate,△OF=changeof theobjectivefunctionvaluerelative to thenull model thatdoesnotincludeanyparameters.

aECOG=2representspatientswithECOGscore≥2and inthecovariateanalysiswere comparedtothosewithECoGscore&lt;2.

bBINET=3representspatientswithBinetstageCand in thecovariateanalysiswerecompared tothosewithBinetstageA.

compared to those from the other regions(US/Canada,Australia/NewZealand,WesternEurope and Latin America).

## · Exposure-Dose Intensity Analyses

Dose intensity was calculated as the total cumulative dose actually received divided by the cumulative planned dose. The planned (target) dose of venetoclax was 400 mg and the cumulative planned dose was calculated from the day when a patient first received the 400 mg dose of venetoclax (Cycle 2, Day 22) until the last actual dose of venetoclax received. The maximum total planned duration of venetoclax treatment after reaching target dose in this approach for calculating dose intensity was 287 days (9.6 months).

The median duration of exposure to venetoclax, from first venetoclax dose, was 315.0 days (10.5 months) (range: 1-406 days [13.5 months]). After reaching the target dose, the median dose intensity for venetoclax was 97.5% (range: 14%-100%).

Obinutuzumab mean dose intensities in venetoclax + obinutuzumab arm were comparable across venetoclax exposure tertials and were between 92.5% and 97.2% for all tertials of venetoclax exposure. Venetoclax mean dose intensities in venetoclax + obinutuzumab arm were comparable across venetoclax exposure tertials and were between 81.1% and 89.3% for all tertials of venetoclax exposure.

<div style=\"page-break-after: always\"></div>

Figure 7. Venetoclax and Obinutuzumab Dose Intensity versus Venetoclax Exposure

Circlescorrespond toindividualdoseintensityvalues.Cmeanss,nominal definedbyEq.1wasusedasa measure ofexposure.Left:Red lines arethelowesstrend lines.Right:The distributionsof venetoclax andobinutuzumabdoseintensityusingboxandwhiskerplots.Medianvaluesaredesignatedbyblack linesinthe centerof theboxes.Boxesindicate theinter-quartilerange(IQR).Whiskersrepresent 1.5*IQR

<!-- image -->

## · Exposure-Efficacy Analyses

A total of 27 (13.3%) and 26 (12.8%) patients had INV and IRC- assessed progression events, respectively. The KM plots stratified by tertials and quartiles of venetoclax exposure and CPH models indicated no venetoclax exposure-PFS relationships. Risk of progression or death was lower in patients with t12 trisomy (p &lt; 0.01). None of the covariates were significant at α = 0.01 level.

<div style=\"page-break-after: always\"></div>

Figure 8. Kaplan-Meier Analysis of Time to Progression (Investigator Data) (A; tertials, B; quartiles) and Time to Progression (IRC Data) (C; tertials, D; quartiles)

36

<!-- image -->

4th:

<div style=\"page-break-after: always\"></div>

Table 17. Final CPH Models for PFS

| Parameter                                          | β                                                  | SE                                                 | RSE (%)                                            | p-value                                            |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Investigator Data: CmeanSs,nominal + factor(T12=1) | Investigator Data: CmeanSs,nominal + factor(T12=1) | Investigator Data: CmeanSs,nominal + factor(T12=1) | Investigator Data: CmeanSs,nominal + factor(T12=1) | Investigator Data: CmeanSs,nominal + factor(T12=1) |
| CmeanSS,nominal                                    | -0.5053                                            | 0.5346                                             | 105.79                                             | 0.34                                               |
| T12 = 1                                            | -18.29                                             | 4099                                               | 22412.19                                           | a0.0020                                            |
| IRC Data: CmeansS,nominal + factor(T12=1)          | IRC Data: CmeansS,nominal + factor(T12=1)          | IRC Data: CmeansS,nominal + factor(T12=1)          | IRC Data: CmeansS,nominal + factor(T12=1)          | IRC Data: CmeansS,nominal + factor(T12=1)          |
| CmeanSS,nominal                                    | -0.59                                              | 0.5531                                             | 93.75                                              | 0.29                                               |
| T12 = 1                                            | -18.29                                             | 4197                                               | 22951.99                                           | b0.0026                                            |

## 2.3.4. Discussion on clinical pharmacology

The bioanalysis methods for both venetoclax and obinutuzumab were not changed since their respective original application and were therefore not re-assessed. The same is true for the ADA method.

QCs and calibration curves were within the acceptance criteria in the analytical runs for studies BO25323 and GP28331, for both venetoclax and obinutuzumab. ISR was performed and passed in all studies where it was required. No ISR was performed in study BO25323 for venetoclax, but ISR was passed (95.1% of 41 study samples were within ±30%) for obinutuzumab. During the analysis of study GP28331 samples, the sample preparation for venetoclax was changed from solid phase extraction to liquid/liquid extraction. This change of method was adequately validated using the ISR with 16 samples, where all met the acceptance criteria. 130 samples were reanalyzed for obinutuzumab and 80.8% of them passed the ISR acceptance criteria. ADA analysis (screening, confirmation &amp; titration) was performed only in study GP28331. No ADAs were detected in the patients´ samples. No NAb analysis was performed.

The purpose of the PopPK model was to confirm that PK of venetoclax did not change with coadministration of obinutuzumab, and to provide the individual subject exposure metrics for an assessment of the exposure-efficacy, exposure-safety and exposure-tolerability relationships for Study BO25323.

The population pharmacokinetic analysis was in general well performed and adequately reported. The methods applied were according to general standards. The goodness-of-fit plots and the dose-normalised visual predictive checks for the final model reveal a reasonable prediction of lower concentrations, however the high concentrations (8 hours post dose samples) are under-predicted. This is also visible in the Goodness of Fit plots.

The diagnostic plots of the model did not indicate any model deficiencies. The model evaluation procedures (prediction-corrected visual predictive check [pc-VPC]) confirmed good predictive abilities of the model and there were no dependencies unaccounted for by the model.

Overall, the PopPK model adequately characterized venetoclax plasma concentrations over time in Studies GP28331 and BO25323. The PK of venetoclax was similar when co-administered with obinutuzumab. The model is sufficient to use for simulations and to evaluate the E-R relationships of venetoclax for Study BO25323. The parameters from the updated model do not differ greatly from the previous estimation.

Venetoclax is a small-molecule Bcl-2 family protein inhibitor that binds with high affinity to Bcl-2 and with much lower affinity to other Bcl-2 family proteins like Bcl-XL, Bcl-w. Venetoclax can restore programmed

<div style=\"page-break-after: always\"></div>

cell death (apoptosis) in cancer cells where it has been blocked by high level expression of Bcl-2. Obinutuzumab is a novel, humanized, type II glycoengineered MAb directed against the CD20 antigen, which is found on most malignant and benign cells of B-cell origin. Obinutuzumab has the following characteristics:  high-affinity binding to the CD20 antigen, low complement-dependent cytotoxicity activity, high direct cell death induction, and high antibody-dependent cellular cytotoxicity and antibodydependent cellular phagocytosis.

The objective was to investigate exposure-safety, tolerability and efficacy relationships for venetoclax when co-administered with obinutuzumab. Individual subject CL/F and F1 were derived from the PopPK model and used to calculate CmeanSS,nominal for a 400 mg dose. Dose adjustment were not taken into account analysis, therefore the conclusions made are not supported.

The logistic regression analysis of exposure-safety relationships indicated that there was no statistically significant relationship between venetoclax exposure and the probability of developing Grade ≥ 3 neutropenia, Grade ≥ 3 thrombocytopenia, Grade ≥ 3 infections or serious adverse events. The trend indicated that the probability is lower with increasing exposure, however, these subjects may have reduced their dose, thereby giving arise to this trend

The obinutuzumab dose intensities were comparable across venetoclax exposure tertiles, with the medians equal to 100% for all exposure groups. Venetoclax co-administration did not impact the delivery of obinutuzumab. Some trends are observed for lower venetoclax dose intensities with increasing venetoclax exposures, however, this was not considered clinically relevant given the lack of apparent E-R relationships with the primary efficacy endpoints and the key AEs of interest.

## 2.3.5. Conclusions on clinical pharmacology

Overall, the PopPK model adequately characterised venetoclax plasma concentrations over time in Studies GP28331 and BO25323. The PK of venetoclax was similar when co-administered with obinutuzumab. The model is sufficient to use for simulations and to evaluate the E-R relationships of venetoclax for Study BO25323.

The Applicant investigated exposure-safety, tolerability and efficacy relationships for venetoclax when coadministered with obinutuzumab.  The clinical pharmacology aspects of the proposed indication are adequately studied.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

Study GP28331, A phase Ib multicenter dose-finding and safety study of venetoclax and obinutuzumab in patients with relapsed or refractory or previously untreated CLL.

The rationale for selection of the recommended dose and regimen for venetoclax in combination with obinutuzumab in the treatment of previously untreated CLL patients with coexisting medical conditions in the Pivotal StudyBO25323 was based on available information, from the Phase I dose-escalation Study M12-175 and is further supported by the Phase Ib dose-finding/safety Study GP28331 of venetoclax in combination with obinutuzumab in patients with R/R or previously untreated chronic lymphocytic leukemia.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## Study BO25323/CLL14

A prospective, open-label, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions.

Cutoff date: August 2018.

## Methods

The study had a safety run-in with 12 patients. The stopping criteria (i.e. one treatment-related death or one gr4 AE related to a clinical TLS despite protocol-specified prophylaxis, either following the administration of the first dose of venetoclax or during dose escalation) were not met and the Applicant proceeded to the randomized portion.

Figure 9: Study design

<!-- image -->

## Study participants

Main inclusion criteria

- Previously untreated CLL (iwCLL criteria) requiring treatment
- Total Cumulative Illness Rating Score (CIRS)&gt;6 or CrCl&lt;70 mL/min
- Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as follows, unless cytopenia was due to marrow involvement of CLL:
- -Absolute neutrophil count&gt;1.0 x 10 9 /L
- -Platelet counts&gt;30 x 10 9 /L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator); platelet count had to be &gt;10 x 10 9 /L if there was bone marrow involvement
- -Total hemoglobin&gt;9 g/dL without transfusion support, unless anemia was due to marrow involvement of CLL
- Adequate liver function

## Main exclusion criteria

- Transformation of CLL to aggressive NHL (Richter's transformation or pro -lymphocytic leukemia)
- Known central nervous system involvement
- Patients with a history of confirmed progressive multifocal leukoencephalopathy

<div style=\"page-break-after: always\"></div>

- An individual organ/system impairment score of 4 as assessed by the CIRS definition limiting the ability to receive the treatment regimen with the exception of eyes, ears, nose, throat organ system
- Patients with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
- Inadequate renal function: CrCl&lt;30 mL/min
- Patients with infections requiring IV treatment within the last 2 months prior to enrolment
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products

## Treatments

The safety run-in included 13 patients (VEN+G). Once the twelfth patient had reached the end of cycle 3 the randomized portion began. A total of 432 patients were randomized.

The treatment duration in both groups (VEN+G vs GClb) consisted of 12 cycles lasting 28 days each. No crossover was allowed. Obinutuzumab was administered iv for 6 cycles starting with 100 mg on day 1 and 900 mg on day 2 (or 1000 mg on day 1), 1000 mg on day 8 and 1000 mg on day 15 of cycle 1, and subsequently 1000 mg on day 1 of cycles 2 through 6. Chlorambucil was administered orally at 0.5 mg per kilogram of body weight on days 1 and 15 of each cycle until completion of 12 cycles. The daily oral venetoclax regimen was initiated on day 22 of cycle 1, starting with a 5-week dose ramp-up (1 week each of 20, 50, 100, and 200 mg, then 400 mg daily for 1 week), thereafter continuing at 400 mg daily until completion of cycle 12. The risk of tumor lysis syndrome (TLS) was assessed on the basis of the absolute lymphocyte count and lymph-node size to guide prophylactic measures. Criteria for dose modifications were specified in the study protocol.

## Objectives

## Efficacy

Primary: to determine efficacy by investigator-assessed PFS

Secondary efficacy objective: to determine efficacy as assessed by PFS (IRC), overall response, complete response, and MRD response rate as measured by allele-specific oligonucleotide polymerase chain reaction [ASO-PCR])

Note: IRC-assessed PFS was primary endpoint for United States regulatory purposes.

## Safety

Nature, frequency, and severity AEs and SAEs.

## Patient-reported outcomes

To compare disease and treatment-related symptoms following study treatments as measured by M.D. Anderson Symptom Inventory (MDASI-CLL) and to evaluate changes in physical functioning, role functioning, and global health status/quality of life following study treatments as measured by EORTC QLQ-C30.

## Health economics

To compare the health utility effect of study treatments as measured by EQ-5D-3L.

## Outcomes/endpoints

Primary endpoint: PFS, investigator-assessed defined as time from randomization to the first occurrence of progression or relapse (determined using standard iwCLL guidelines or death from any cause, whichever occurred first).

<div style=\"page-break-after: always\"></div>

Key secondary endpoints:

- PFS-IRC
- ORR defined as rate of a clinical response of CR, CRi, or PR at the completion of treatment assessment (EOT assessment i.e., 3 months after treatment completion/early termination), as determined by the investigator
- CR rate: CR Rate is defined as rate of a clinical response of CR or CRi at the completion of treatment assessment (EOT assessment i.e., 3 months after treatment completion/early termination), as determined by the investigator
- MRD negativity: MRD response rate (determined as the proportion of patients with MRD negativity -where MRD negativity was defined as  10 -4  [less than 1 cell in 10,000 leukocytes]) measured in both peripheral blood and bone marrow at the completion of treatment assessment (EOT assessment i.e., 3 months after treatment completion/early termination), both measured by ASO-PCR.
- ORR at the completion of combination treatment
- MRD at the completion of the combination treatment
- MRD response rate in patients with CR
- OS: The time between the date of randomization and the date of death due to any cause. Patients who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.
- DOR: The time from the first occurrence of a documented overall response (CR, CRi, or PR, as assessed by the investigator) to the first occurrence of progression or relapse as determined by the investigator or death from any cause.
- Time to next line therapy: time between the date of randomization and the date of first intake of next line therapy or death from any cause.
- PROs

## Sample size

The sample size for the study was determined given the requirements to perform a hypothesis test for clinically relevant statistical superiority in the primary endpoint of PFS.

Estimates of the number of events required to demonstrate efficacy with regard to PFS were based on the following assumptions:

- Log-rank test at the two-sided 0.05 level of significance
- Median PFS for GClb control arm (27 months)
- 80% power to detect HR = 0.65 for the comparison of VEN + G experimental arm versus GClb, with median PFS for VEN + G increased to 41.5 months
- Exponential distribution of PFS
- Annual drop-out rate of 10%

One interim analysis for efficacy after 75% of PFS events, utilizing a stopping boundary according to the  family error spending function with parameter  = -9.21.

The addition of an optional early interim analysis (performed after 85 events [50% of PFS events] as per Protocol amendment 7 required no adjustment to the sample size, as the impact on the statistical power calculation was negligible.

<div style=\"page-break-after: always\"></div>

Based on these assumptions, a total of 170 PFS events is required for the final PFS analysis of PFS.

## Randomisation

Patients were assigned in 1:1 ratio to one of the two treatment arms (VEN + G or GClb) through a block stratified randomization procedure. The randomization scheme ensured approximately equal sample sizes in the two treatment groups with regards the following stratification factors:

- Binet stage (3 levels): A, B, or C
- Geographic region (US/Canada/Central America; Australia/New Zealand; Western Europe; Central and Eastern Europe; or Latin America)

## Blinding (masking)

This was an open-label study. The IRC and the sponsor were blinded to treatment arm.

## Statistical methods

Treatment comparisons were made using a two-sided log-rank test (at 0.05 significance level, adjusted for the interim analyses), stratified by Binet stage and Geographic Region. If the null hypothesis was rejected and the observed HR was favourable for the VEN + G experimental arm, then it was to be concluded that VEN + G significantly lowered the risk of PFS events more than GClb. A two-sided nonstratified log-rank test was performed to support the primary analysis.

Median PFS and the 95% confidence limits will be estimated using Brookmeyer Crowley method, with the Kaplan-Meier survival curve presented to provide a visual description. PFS rates for 1, 2, and 3 years after randomization with 95% CIs using Brookmeyer Crowley method will be reported. Estimates of the treatment effect will be expressed as HR including 95% confidence limits estimated through a Cox proportional-hazards analysis stratified by Binet stage and Geographic Region.

For patients who were alive and had not had disease progression or relapse, PFS data were censored on the date of the last disease assessment. In the analysis of MRD negativity and response to treatment, patients without a sample or response assessment that could be evaluated were counted as not being negative for residual disease or as not having a response, respectively.

If the study meets the primary efficacy endpoint of investigator assessed PFS, then the formal statistical testing procedure for the key secondary endpoints will be performed using alpha-splitting and recycling of alpha. To adjust for multiple testing, the pre-specified hierarchical testing of eight key secondary efficacy endpoints was used in the following order:

1. Independent review committee-assessed PFS
2. Minimal residual disease in bone marrow 3 months after treatment completion
3. Complete response rate [investigator-assessed] 3 months after treatment completion
4. Minimal residual disease in peripheral blood 3 months after treatment completion
5. Minimal residual disease in complete response in bone marrow 3 months after treatment completion
6. Minimal residual disease in complete response in peripheral blood 3 months after treatment completion
7. Overall response rate [investigator-assessed] 3 months after treatment completion
8. Overall survival

<div style=\"page-break-after: always\"></div>

The d-spending boundary of each endpoint at the interim analysis is given as follows:

<!-- image -->

|    | Endpoint                                                                                              |   α Spend at Interim Analysis |
|----|-------------------------------------------------------------------------------------------------------|-------------------------------|
|  1 | Independent review committee-assessed PFS                                                             |                        0.0019 |
|  2 | Minimal residual disease in bone marrow 3 months after treatment completion                           |                        0.0019 |
|  3 | Complete response rate [investigator-assessed] 3 months after treatment completion                    |                        0.05   |
|  4 | Minimal residual disease in peripheral blood 3 months after treatment completion                      |                        0.05   |
|  5 | Minimal residual disease in complete response in bone marrow 3 months after treatment completion      |                        0.05   |
|  6 | Minimal residual disease in complete response in peripheral blood 3 months after treatment completion |                        0.05   |
|  7 | Overall response rate [investigator-assessed] 3 months after treatment completion                     |                        0.05   |
|  8 | Overall survival                                                                                      |                        0.007  |

To check robustness of the primary analysis of PFS and underlying assumptions, the following sensitivity analyses for PFS (both investigator-assessed and IRC-assessed) will be performed on the ITT population:

- An unstratified log-rank test for the primary PFS comparison between treatment arms will be conducted.
- The impact of patients' initiation of non -protocol specified anti-CLL therapy without meeting the criteria of disease progression/relapse on PFS will be assessed by censoring these patients at the start date of the non-protocol specified anti-CLL treatment. Stopping only one component of the randomized study treatment will not be considered a reason for censoring patients.
- To assess the impact of missing assessments on PFS, an analysis on PFS will be performed by censoring those patients who progressed, relapsed or died after missing more than one visit consecutively at their last adequate response assessment date before the missed visits.

The primary and secondary analyses were based on the ITT population, defined as all randomized patients. Subgroup analyses of investigator-assessed PFS, IRC-assessed PFS, MRD, ORR, CR and OS were performed to assess internal consistency using the ITT population. The odds ratios of response and their 95% confidence intervals, HR of time-to-event endpoints and their 95% confidence intervals (based on similar analyses to the primary endpoint), as well as the sample sizes were reported separately for each level of the following subgroups in forest plots by baseline characteristics and stratification factors (Binet stage and Region).

Originally an interim analysis for efficacy were planned once a minimum of 110 PFS events have occurred. PFS were to be tested at the significance level determined using the gamma family error spending fu nction with parameter γ=-9.21 so that the overall two -sided type I error rate will be maintained at the 0.05 level. In protocol amendment 7 an optional early interim analysis (at a minimum of 85 events) was included, if this was performed and passed, this later original interim analysis was not to be undertaken.

The final analysis was designed to be conducted after 170 events have occurred. venetoclax dose, then the interim analysis may be conducted once a minimum of 85 PFS events have occurred.

Also, exploratory analyses were performed, including graphical analyses, of the relationship between MRD (on the basis of peripheral blood results by ASO-PCR) and PFS.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 10 Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

Out of 514 patients assessed for eligibility in the main study, 432 were enrolled, 216 in each arm; 186/216 patients in VEN+G and 190/216 in GClb were ongoing at cutoff (Aug. 2018).

## Conduct of the study

There were 6 protocol amendments.

## Baseline data

| Characteristic                                                 | Venetoclax-Obinutuzumab (N=216)   | Chlorambucil-Obinutuzumab (N=216)   |
|----------------------------------------------------------------|-----------------------------------|-------------------------------------|
| Age ≥75 yr— no. (%)                                            | 72 (33.3)                         | 78 (36.1)                           |
| Male sex — no. (%)                                             | 146 (67.6)                        | 143 (66.2)                          |
| Binet stage — no. (%)↑                                         |                                   |                                     |
| A                                                              | 46 (21.3)                         | 44 (20.4)                           |
| B                                                              | 77 (35.6)                         | 80 (37.0)                           |
| C                                                              | 93 (43.1)                         | 92 (42.6)                           |
| Tumor lysis syndrome risk category— no. (%)                    |                                   |                                     |
| Low                                                            | 29 (13.4)                         | 26 (12.0)                           |
| Intermediate                                                   | 139 (64.4)                        | 147 (68.1)                          |
| High                                                           | 48 (22.2)                         | 43 (19.9)                           |
| Total CIRS score >6 —— no. (%)                                 | 186 (86.1)                        | 177 (81.9)                          |
| Calculated creatinine clearance <70 ml/min—— no./total no. (%) | 128/215 (59.5)                    | 118/213 (55.4)                      |
| Cytogenetic subgroup — no./total no. (%)§                      |                                   |                                     |
| Deletion in 17p                                                | 17/200 (8.5)                      | 14/193 (7.3)                        |
| Deletion in 1lq                                                | 36/200 (18.0)                     | 38/193 (19.7)                       |
| Trisomy 12                                                     | 36/200 (18.0)                     | 40/193 (20.7)                       |
| No abnormalities                                               | 50/200 (25.0)                     | 42/193 (21.8)                       |
| Deletion in 13q alone                                          | 61/200 (30.5)                     | 59/193 (30.6)                       |
| IGHV mutational status — no./total no. (%)                     |                                   |                                     |
| Mutated                                                        | 76/200 (38.0)                     | 83/208 (39.9)                       |
| Unmutated                                                      | 121/200 (60.5)                    | 123/208 (59.1)                      |
| Could not be evaluated                                         | 3/200 (1.5)                       | 2/208 (1.0)                         |
| TP53 mutational status — no./total no. (%)                     |                                   |                                     |
| Mutated                                                        | 19/171 (11.1)                     | 13/157 (8.3)                        |
| Unmutated                                                      | 152/171 (88.9)                    | 144/157 (91.7)                      |

<div style=\"page-break-after: always\"></div>

The patients were elderly (median age, 72 years; range: 41 to 89; 34.7% were aged over 75 years) and white (89.4%). Approximately two-thirds of patients (66.9%) were male. The majority of patients were enrolled in Europe, 69.7%. Overall, the median time from first diagnosis of CLL to randomization was 2.5 years (0-20.4 years). The majority of patients were Binet stage B or C (79.1%) at baseline and approximately half (49.8%) were experiencing B symptoms at baseline, with night sweats (43.5%) being the most frequent B symptom. TLS risk was categorized as low, medium or high and the risk categories were balanced between groups: 43 patients (20%) in the GClb arm and 48 (22.2%) in the VEN+G arm belonged to the high- risk category). The majority of patients (66.2%) were considered as intermediate risk.

The proportion of patients with unmutated IGVH mutational status (based on central assessment) was 57% in the GClb arm and 56% in the VEN+G arm; 10 patients in the GClb arm (4.6%) and 19 in the VEN+G arm (8.8%) either had missing samples or were not evaluable for IGVH mutational status. The TP53 mutation was carried by 13 patients (6%) in the GClb arm and 19 patients (8.8%) in the VEN+G arm. The mutational status was unknown for 59 patients (27.3%) in the GClb arm and 45 (20.8%) in the VEN+G arm. The 17p deletion was present in 14 patients (7.3%) in the GClb arm and 17 patients (8.5%) in the VEN+G arm.

The median CIRS score was numerically higher in the VEN+G arm (9 vs 8 in the GClb arm), and the proportion of patients with CIRS score of &gt;6 was 86.1% compared with 81.9%, respectively. The proportion of patients with creatinine clearance &lt;70 mL/min was 55.4% in the GClb arm and 59.5% in the VEN+G arm.

In terms of prognosis, the CLL-IPI scores were similar for the two treatment arms; 60% in the GClb arm and 60.4% in the VEN+G arm had a high score.

CIRS: 177 patients (81.9%) in the GClb arm and 186 (86.1%) in the VEN+G arm had a CIRS score &gt;6. Most patients in each treatment arm had comorbidities in 4-8 organ systems (179 patients [82.9%] in both arms). A higher percentage of patients in the VEN+G group had involvement of cardiac systems and hypertension, followed by respiratory organ system.

As for concurrent diseases, vascular disorders were the most frequent type of concurrent medical condition: GClb 155 (71.8%) compared with 175 (81%) in the experimental arm, mainly due to hypertension; COPD: 11 patients (5.1%) in the GClb arm vs 18 (8.3%) in the VEN+G arm; asthma 6 (2.8%) vs 10 (4.6%), respectively.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

## Outcomes and estimation

## Table 18 Efficacy outcomes

|                                                             | GClb                                                        | VEN + G                                                     |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Parameter a                                                 | (N = 216)                                                   | (N = 216)                                                   |
| Progression-Free Survival (Investigator Assessment)         | Progression-Free Survival (Investigator Assessment)         | Progression-Free Survival (Investigator Assessment)         |
| Patients with event                                         | 77 (35.6%)                                                  | 30 (13.9%)                                                  |
| Time to event (months)                                      |                                                             |                                                             |
| Median [95% CI]                                             | NE [31.1, NE]                                               | NE [NE]                                                     |
| P-value (log-rank test, stratified)                         | p  0.0001                                                  | p  0.0001                                                  |
| Hazard ratio (stratified), [95% CI]                         | 0.35 [0.23, 0.53]                                           | 0.35 [0.23, 0.53]                                           |
| Estimate of 1-year PFS rate %(95% CI)                       | 92.11 (88.40, 95.82)                                        | 94.62 (91.53, 97.71)                                        |
| Estimate of 2-year PFS rate %(95% CI)                       | 64.10 (57.39, 70.81)                                        | 88.15 (83.69, 92.60)                                        |
| Progression-Free Survival (IRC Assessment)                  | Progression-Free Survival (IRC Assessment)                  | Progression-Free Survival (IRC Assessment)                  |
| Patients with event                                         | 79 (36.6%)                                                  | 29 (13.4%)                                                  |
| Time to event (months)                                      |                                                             |                                                             |
| Median [95% CI]                                             | NE [31.1, NE]                                               | NE [NE]                                                     |
| P-value (log-rank test, stratified)                         | p  0.0001                                                  | p  0.0001                                                  |
| Hazard ratio (stratified), [95% CI]                         | 0.33 [0.22, 0.51]                                           | 0.33 [0.22, 0.51]                                           |
| Estimate of 1-year PFS rate %(95% CI)                       | 91.16 (87.27, 95.06)                                        | 94.60 (91.50, 97.71)                                        |
| Estimate of 2-year PFS rate %(95% CI)                       | 63.70 (56.99, 70.42)                                        | 88.59 (84.20, 92.98)                                        |
| Overall Response Rate (Investigator Assessment) b (EOT)     | Overall Response Rate (Investigator Assessment) b (EOT)     | Overall Response Rate (Investigator Assessment) b (EOT)     |
| Responders                                                  | 154 (71.3%)                                                 | 183 (84.7%)                                                 |
| 95% CI                                                      | [64.77, 77.23]                                              | [79.22, 89.24]                                              |
| Difference in response rates [95% CI]                       | 13.43 [5.47, 21.38]                                         | 13.43 [5.47, 21.38]                                         |
| P-value (CMH test)                                          | p = 0.0007                                                  | p = 0.0007                                                  |
| Complete Response Rate(Investigator Assessment) b (EOT)     | Complete Response Rate(Investigator Assessment) b (EOT)     | Complete Response Rate(Investigator Assessment) b (EOT)     |
| Responders                                                  | 50 (23.1%)                                                  | 107 (49.5%)                                                 |
| 95% CI                                                      | [17.70, 29.35] [42.68, 56.40]                               | [17.70, 29.35] [42.68, 56.40]                               |
| Difference in response rates [95% CI]                       | 26.39 [17.41, 35.36]                                        | 26.39 [17.41, 35.36]                                        |
| P-value (CMH test)                                          | p  0.0001                                                  | p  0.0001                                                  |
| MRD-Negativity Rate-Peripheral Blood b (EOT)                | MRD-Negativity Rate-Peripheral Blood b (EOT)                | MRD-Negativity Rate-Peripheral Blood b (EOT)                |
| MRD negative (at 10 -4 )                                    | 76 (35.2%)                                                  | 163 (75.5%)                                                 |
| 95% CI                                                      | [28.83, 41.95] [69.17, 81.05]                               | [28.83, 41.95] [69.17, 81.05]                               |
| Difference in MRD negative rates [95% CI]                   | 40.28 [31.45, 49.10]                                        | 40.28 [31.45, 49.10]                                        |
| P-value (CMH test)                                          | p  0.0001                                                  | p  0.0001                                                  |
| MRD-Negativity Rate-Bone Marrow b (EOT)                     | MRD-Negativity Rate-Bone Marrow b (EOT)                     | MRD-Negativity Rate-Bone Marrow b (EOT)                     |
| MRD negative (at 10 -4 )                                    | 37 (17.1%)                                                  | 123 (56.9%)                                                 |
| 95% CI                                                      | [12.36, 22.83]                                              | [50.05, 63.64]                                              |
| Difference in MRD negative rates [95% CI]                   | 39.81 [31.27, 48.36]                                        | 39.81 [31.27, 48.36]                                        |
| P-value (CMH test)                                          | p  0.0001                                                  | p  0.0001                                                  |
| MRD-Negativity Rate in CR c Patients-Peripheral Blood (EOT) | MRD-Negativity Rate in CR c Patients-Peripheral Blood (EOT) | MRD-Negativity Rate in CR c Patients-Peripheral Blood (EOT) |
| Responders                                                  | 31 (14.4%)                                                  | 91 (42.1%)                                                  |
| 95% CI                                                      | [9.96, 19.75] [35.46, 49.02]                                | [9.96, 19.75] [35.46, 49.02]                                |
| Difference in MRD responder rates [95% CI]                  | 27.78 [19.45, 36.10]                                        | 27.78 [19.45, 36.10]                                        |
| P-value (CMH test)                                          | p  0.0001                                                  | p  0.0001                                                  |

EOT = at end of treatment (i.e., 3  months after treatment completion/early termination); MRD: minimum residual disease;  a  Key secondary response rates were also compared using a stratified test (according to the  hierarchical testing approach), b  By ASO-PCR,  c CR status is assessed by investigator,  d  As of clinical cut-off, the overall survival data were immature to be meaningful.

<div style=\"page-break-after: always\"></div>

Table 19: PFS (inv. assessed)

<!-- image -->

95t Cl for median was computed uging the method of Brooloneyer and Crowley. Haeard ratios were estimnted by Con regression model.

estinates.

Stratification factors: Binet and Geographie region.

At the interim analysis (specified at 110 events, with 107 actual events), the number of PFS events in the control arm was low, 35.6%. Despite a median follow-up of approximately 29 months for each arm, the PFS data can be considered immature. From around month 23 and on, extensive censoring is observed.

<div style=\"page-break-after: always\"></div>

Figure 11 K-M of PFS (investigator assessed)

VenetoclaxInterimAnalysis-Based onDataasof ClinicalDataCutoffDate:17AUG2018 AnalysisPopulation:Intent-to-TreatPatients-Phase lll

Figure 12: PFS by IRC

<!-- image -->

VenetoclaxInterimAnalysis-BasedonData asof Clinical DataCutoffDate:17AUG2018 AnalysisPopulation:Intent-to-Treat Patients-Phase Ill

<!-- image -->

The reported concordance between investigator and IRC is very high (98.1%).

## Sensitivity analyses for PFS

Three sensitivity analyses of investigator-assessed PFS were conducted to test for the potential impact of differences in modelling or censoring approaches:

1. A non-stratified log-rank test
2. PFS analyses with censoring at initiation of non-protocol-specified anti-CLL therapy before meeting disease progression criteria to assess potential confounding of treatment effect estimates by subsequent therapy
3. PFS analyses with censoring of death or disease progression after more than one missed response assessment at the date of last adequate response assessment

<div style=\"page-break-after: always\"></div>

Table 20 Sensitivity analyses for PFS

<!-- image -->

|                                                        | INV-Assessed PFS                                       | INV-Assessed PFS                                       | IRC-Assessed PFS                                       | IRC-Assessed PFS                                       |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Analysis                                               | GCIb arm                                               | VEN+G arm                                              | GClb arm                                               | VEN+G arm                                              |
| Censoring for More Than One Missed Response Assessment | Censoring for More Than One Missed Response Assessment | Censoring for More Than One Missed Response Assessment | Censoring for More Than One Missed Response Assessment | Censoring for More Than One Missed Response Assessment |
| Patients with event                                    | 75 (34.7%)                                             | 28 (13.0%)                                             | 77 (35.6%)                                             | 27 (12.5%)                                             |
| Median Time to Event (months)                          | NE (31.1, NE)                                          | NE (NE)                                                | NE (31.1, NE)                                          | NE (NE)                                                |
| Stratified P-value (log-rank)                          | <.0001                                                 | <.0001                                                 | <.0001                                                 | <.0001                                                 |
| Stratified HR (CI 95%)                                 | 0.33 (0.22,0.52)                                       | 0.33 (0.22,0.52)                                       | 0.32 (0.21, 0.50)                                      | 0.32 (0.21, 0.50)                                      |
| Unstratified P-value (log- rank)                       | <.0001                                                 | <.0001                                                 | <.0001                                                 | <.0001                                                 |
| Unstratified HR (CI 95%)                               | 0.32 (0.21, 0.50)                                      | 0.32 (0.21, 0.50)                                      | 0.30 (0.20, 0.47)                                      | 0.30 (0.20, 0.47)                                      |
| Censoring for new anti-CLL Treatmentb                  | Censoring for new anti-CLL Treatmentb                  | Censoring for new anti-CLL Treatmentb                  | Censoring for new anti-CLL Treatmentb                  | Censoring for new anti-CLL Treatmentb                  |
| Patients with event                                    | 77 (35.6%)                                             | 29 (13.4%)                                             | 78 (36.1%)                                             | 28 (13.0%)                                             |
| Median Time to Event (months)                          | 139 (64.4%)                                            | 187 (86.6%)                                            | NE (31.1, NE)                                          | NE (NE)                                                |
| Stratified P-value (log-rank)                          | <.0001                                                 | <.0001                                                 | <.0001                                                 | <.0001                                                 |
| Stratified HR (CI 95%)                                 | 0.34 (0.22,0.52)                                       | 0.34 (0.22,0.52)                                       | 0.33 (0.21, 0.50)                                      | 0.33 (0.21, 0.50)                                      |
| Unstratified P-value (log- rank)                       | <.0001                                                 | <.0001                                                 | <.0001                                                 | <.0001                                                 |
| Unstratified HR (CI 95%)                               | 0.33 (0.21, 0.50)                                      | 0.33 (0.21, 0.50)                                      | 0.31 (0.20, 0.48)                                      | 0.31 (0.20, 0.48)                                      |

## Secondary endpoints

A higher number of patients treated with VEN+G had an Overall Response in comparison to the GClb arm per investigator assessment (84.7% vs 71.3% where a difference of 13.43% seen in the response rates (95% CI:5.47,21.38) p value = 0.0007 stratified Cochran-Mantel-Haenszel test.

Likewise for CR/CRi, patients treated with VEN+G achieved a higher rate of CR/Cri compared with patients in the GClb arm as per investigator assessment (49.5% vs 23.1%,difference in response rate:26.39,95% CI 17.41,35.36 [p value &lt;0.0001,stratified Cochran-Mantel-Haenszel test

<div style=\"page-break-after: always\"></div>

ORR and CR Table 21: ORR and CR results

<!-- image -->

## MRD

MRD responses comprised 1) peripheral blood MRD assessment in all patients and 2) bone marrow MRD assessment in responders (CR+PR). ASO-PCR MRD was assessed 3 months after treatment completion/early termination for all patients (PB and BM) and across pre-specified time-points for PB (every 3 mo for 18 months from EOT and thereafter every 6 months until 5 years from last patient enrolled). The patients for whom no post-baseline MRD assessment was available at a specific time-point were considered MRD positive for that particular time-point. The status recorded for missing bone marrow biopsies or missing computed tomographic scans was partial response or stable disease, respectively.

<div style=\"page-break-after: always\"></div>

Table 22 MRD negativity in bone marrow at the EOT visit (ITT)

<!-- image -->

Table 23 MRD negativity in peripheral blood at the EOT visit (ITT)

<!-- image -->

## MRD and clinical outcome

Table 24 MRD negativity (bone marrow) at EOT assessment (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table 25 MRD negativity (peripheral blood) at EOT assessment (ITT population)

<!-- image -->

## DOR

Overall, 197/216 in GClb and 200/216 in VEN+G arm responded to treatment.

Figure 13: EFS

<!-- image -->

Venetoclax Interim Analysis - Based on Data as of Clinical Data Cutoff Date: 17AUG2018 Analysis Population: Intent-to-Treat Patients - Phase Ill

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 14: Time to next line therapy

<!-- image -->

Table 26: time to next therapy

|                                                                                                                   | GClb (N=216)                         | VEI+G (N=216)              |
|-------------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------------------|
| Patients with event (B) Earliest contributing event New anti-leukemic treatment Death Patients without event (B)d | 45(20.88) 32 13 171 (79.28)          | 27(12.51) 10 17 189(87.54) |
| Time to Event (Month) Wadien 954 C1 251 end 75t-ile Renge                                                         | NE [34.6. NE) 34.6, NE 0.0* to 35.9* | E E NE 0.0* to 35.4*       |
| Stratified Analysig P-value (log-tank)                                                                            |                                      | 0.0340                     |
| Hanard Ratio 954 CI                                                                                               |                                      | 0.60 (0.37,0.97)           |
| Unstratified Analygi: p-value (log-rank)                                                                          |                                      | 0.0285                     |
| Hasard Ratio 954 CI                                                                                               |                                      | 0.59 (0.37,0.95)           |
| Time Point Analysig 6 Honth Duration Patientg remaining at risk Euent Free Rata (6) 951 CI                        | 203 96.24 (93.69,98.80)              | 198 95.67 (92.91,98.44)    |
| 12 Month Duration Patients remaining. Et risk Event Free Rate 95: CI                                              | 194 92.91 (89.44,96.37)              | 195 94.22 (91.05, 97.40)   |
| 18 Month Duration Patients remaining at risk Event Free Rate (b) 951 C1                                           | 183 88.09 (83.71, 92.48)             | 189 91.32 (87.49, 95.15)   |
| 24 Month Duration Patientg remaining. at risk Event Free 1 Rate (6) 951 C1                                        | 166 82.30 (77.12, 87.48)             | 177 89.38 (85.19, 93.58)   |
| 30 Month Duration Patients remaining at risk Event Free Rata 951 CI                                               | 66 78.71 (72.83,84.58)               | 89 87.96 (83.36, 92.57)    |

Venetoclax Interim Analysis - Based on Data as of Clinical Data Cutoff Date: 17AUG2018 Analysis Population: Intent-to-Treat Patients - Phase Ill

<!-- image -->

<div style=\"page-break-after: always\"></div>

## OS

At the data cut-off less than 10% of enrolled patients had died: 7.9% (17/216) OS events in GClb and 9.3% (20/216) in VEN+G.

Figure 15: Overall Survival

Venetoclax Interim Analysis - Based on Data as of Clinical Data Cutoff Date: 17AUG2018 Analysis Population: Intent-to-Treat Patients - Phase Ill

<!-- image -->

## PROs

MDASI-CLL, EORTC QLC-C30 and EQ-5D-3L analyses did not show a difference between treatments.

## Ancillary analyses

Pre-specified subgroup analyses of investigator-assessed PFS and MRD negativity in peripheral blood 3 months after treatment completion were performed to assess internal consistency using the ITT population.

Pre-specified subgroups included: Binet stage at screening (A, B, C), Age (&lt;75, ≥ 75), Gender (male, female), Cytogenetic factors (deletion 17p, 11q and 13q, and trisomy 12), TP53 status (deletion and/or mutation, none), IGVH mutational status (unmutated, mutated)

Since the study was powered for the ITT population, all subgroup analyses were exploratory.

<div style=\"page-break-after: always\"></div>

Figure 16: Investigator-assessed PFS by prognostic subgroup

Chlarambusil-

Vensloclas-

<!-- image -->

Figure 17: MRD negativity by ASO-PCR in peripheral blood 3 months after completion of treatment by prognostic subgroup

<!-- image -->

|                                    |                |       | Chonmbucil-cbinutuzunab   | Chonmbucil-cbinutuzunab   | Chonmbucil-cbinutuzunab   | Yenetoclax-cbinutuzunab   | Yenetoclax-cbinutuzunab   | Yenetoclax-cbinutuzunab   |                               |                        |
|------------------------------------|----------------|-------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------------|------------------------|
|                                    |                | Total |                           |                           |                           |                           |                           |                           |                               |                        |
|                                    |                |       |                           | MRD mpaliwe               |                           | HRD mgalwe ()             | Dlda ralle                | 024. 01                   | Chlormbucil- otliaumah bullar | Vareiodat- ahinalzimah |
| Calhgar AI                         | Cutgroap       | 432   | 216                       | 35.1                      | 216                       | 76.5                      | 5.61                      | 1.74-8.61                 |                               | bullur                 |
| Binit stago atstrering             | A              | 91    | 44                        | 40.9                      | 46                        | 81.1                      | 11.84                     | 3.92-35.80                |                               |                        |
|                                    |                | 157   | 00                        | 33.8                      | 17                        |                           | 0.43                      | 3.1112.55                 |                               |                        |
|                                    |                | 18    |                           | 23.1                      |                           | 07.7                      | 1.18                      | 954.761                   |                               |                        |
| Age goups (yeers)                  |                | 282   | 138                       | 31.9                      |                           | 71.1                      | 7.19                      | 4.21-12.19                |                               |                        |
|                                    | 210            | 150   | T8                        | 41.0                      | 12                        | 12.7                      | 3.74                      | 1.887.42                  |                               |                        |
| Candar                             | Nal            | 219   | 141                       | 05.1                      | 14G                       | 74.7                      | 6.31                      | 1.20-0.02:                |                               |                        |
|                                    | Femno          | 143   | 78                        | 24.1                      | 10                        | 71.1                      | 6.48                      | 311-11.58                 |                               |                        |
| Cyteganeie sabgiotps B per hearchy | (detlep        | 31    | 14                        | 7.1                       | 17                        | 70.6                      | 31.20                     | 3.17-305.84               |                               |                        |
|                                    | d1q)           | 74    | 38                        | 26.3                      |                           | 72.2                      | 7.28                      | 2212-192                  |                               |                        |
|                                    |                | 7     | d0                        | d0.0                      |                           |                           | 621                       | 2.20_17.63                |                               |                        |
|                                    | No sbnomaltims | 92    | 42                        | 28.1                      | 0                         | 74.0                      | 4                         | 1.91-11.23                |                               |                        |
|                                    |                | 120   | 55                        | 42.4                      |                           |                           | 5.55                      | 2.4612.55                 |                               |                        |
| TPE dalofien ardlor muutlon        | Frmwont        | di    | 20                        | 0.1                       | 54                        | 70.8                      | 2429                      | 444_02.4                  |                               |                        |
|                                    | Nolpwert       | 287   | 139                       | 36.0                      | 148                       | 76.4                      | 5.75                      | 1.44-960                  |                               | 二                      |
|                                    |                | 244   | 129                       |                           | 121                       | 11.3                      | 10.09                     | 5.518.15                  |                               |                        |
|                                    | Mulalsd        | 119   |                           | 41.4                      | 16                        | 74.7                      | 9.06                      | 1.077.16                  |                               |                        |

The available PFS and MRD data support an effect across cytogenetic subgroups and mutational status.

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 27 Summary of Efficacy for trial BO25323/CLL14

| A prospective, open-label, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions.   | A prospective, open-label, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions.   | A prospective, open-label, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions.   | A prospective, open-label, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                  | BO25323/CLL14                                                                                                                                                                                                                                                     | BO25323/CLL14                                                                                                                                                                                                                                                     | BO25323/CLL14                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                            | Randomized, open-label                                                                                                                                                                                                                                            | Randomized, open-label                                                                                                                                                                                                                                            | Randomized, open-label                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                            | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                    | 2015- (ongoing) 2014-2015 NA                                                                                                                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                        | Superiority                                                                                                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                                 | VEN+G (experiment)                                                                                                                                                                                                                                                | VEN+G (experiment)                                                                                                                                                                                                                                                | 12 cycles, n=216                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                 | GClb (control)                                                                                                                                                                                                                                                    | GClb (control)                                                                                                                                                                                                                                                    | 12 cycles, n=216                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                         | Primary                                                                                                                                                                                                                                                           | PFS                                                                                                                                                                                                                                                               | Inv-assessed                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                         | Secondary                                                                                                                                                                                                                                                         | PFS IRC, ORR, CR, MRD, PROs                                                                                                                                                                                                                                       | PFS IRC was the primary endpoint in the US.                                                                                                                                                                                                                       |
| Database lock                                                                                                                                                                                                                                                     | 17 August 2018                                                                                                                                                                                                                                                    | 17 August 2018                                                                                                                                                                                                                                                    | 17 August 2018                                                                                                                                                                                                                                                    |
| Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              |
| Analysis description                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                  |
| Analysis population and time point description                                                                                                                                                                                                                    | ITT                                                                                                                                                                                                                                                               | ITT                                                                                                                                                                                                                                                               | ITT                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect estimate per   |
|-----------------------|
| comparison            |

<div style=\"page-break-after: always\"></div>

## Supportive study

Study GP28331, A phase Ib multicenter dose-finding and safety study of venetoclax and obinutuzumab in patients with relapsed or refractory or previously untreated CLL.

GP28331 (Phase b) (CCOD: 21 May 2018)

Open-label. Adult patients with · To estimate the maximum tolerated  50 R/R patients and 32 1LVe0etoclex: Orally once daily. multicenter. previously dose (MTD) of venetoclax in -asop untreated CLL orcombination with gkinutuzumeb in finding and with patients with R/R CLL &amp; patients with safety relapsed/refractory previously untreated CLL.

Apnqs patients who received st least starting at 20 mg/day for 1 week, then 2 cycles of combination 50 mg/day for 1 week, and continuing treatment (yenetoclax, and sequentially through each cohort obinutuzumab) - (22 patients each week until the target cohort [16 R/R and 6 1L patients] in  dose was reached (100, 200, 400 dose-findling stage. mg/day), then daily dosing until patients] in safety-expansion Qbinutuzumab IV infusion at stage) 1000 mg at the clinic, with three doses given during Cycle 1 on Days 1, 8, and 15 (first dose split: 100 mg on Day 1 snd 900 mg on Diay 2). snd thereafter on Day 1 of esch subsequent cycle for up to six cycles (each cycle is 28 days).

CLL

· To evaluate the safety and tolersbility I of yenetoclex in combinstion with gkinutuzumab,in patients with R/R CLL58 patients [30 R/R and 26 1L disease progression. &amp;\\_patients with previously untreated CLL

CCOD- clinical cutoff date; CLL- chronic lymphocytic leukemis; IV- intravenous; PFS-progression-free survivsl; PO- per oral; R/R- relapsed or refractory

Enrollment into the safety run-in phase wss completed in April 2015 with 13 pstients. One patient was withdrswn from treatment per protocol due to an analysis. but remsined in the safety population.

bEach cycle is 28 days

cOn Cycle 1 Day 1, start gkinutuzuweb, administrstion at 1000 mg (dose may be split as 100 mg snd 900 mg on Days 1 and 2). Administer 1000 mg on Days 8 and 15 off Cycle 1 and on Dsy 1 of five subsequent cycles (total of 6 cycles, 28 days each).

d400 mg veneteslex, daily / oral tablet / 12 cycles (28 dlays each cycle). Patients undlerwent a ramp-up period, first dose 20 mg starting Day 22 of Cycle 1 and a yo zz Aeg uo Aep Bu o0 Buyoeau

Primary objective: safety and tolerability

Secondary objectives: to estimate OR, DOR, CR, PFS, OS

## Results

- All 1L patients responded to treatment; 25/32 (78.1%) achieved a CR/CRi.
- Consistent overall response rates and deep remissions were observed in all patient subgroups, regardless of cytogenetic factors and/or physical fitness status. Responses were similar among patients with del(17p)/ TP53 mutation or IgVH mutational status.
- The median duration of response was not reached in 1L patients (range: 10.2-33.3 months).  At 1 and 2 years after their first response, the percentage of patients remaining in response to treatment was 93.75% and 90.63%, respectively.
- After a median follow-up of 26.7 months for 1L patients (range: 16-39 months), the 12-month PFS was 100% and at 24 months, the PFS rate was 90.63%.
- Progression of disease occurred in 4 1L patients, 3 of whom had 17p del and/or TP53 mutation at baseline. Among the 22 1L fit patients, 3 (13.6%) had disease progression. Among the subset of 1L fit patients who did not have venetoclax treatment extended beyond 1 year, 1 patient out of 13 (7.7%) had disease progression.
- MRD was negative (e.g., undetectable at a threshold  1 CLL cell per 10000 leukocytes) in peripheral blood of 90.6% (29/32) of 1L patients at least 3 months after the last obinutuzumab dose. Specifically, after at least 3 months from the last venetoclax dose, the rate of undetectable peripheral blood MRD was sustained at 71.9% (23/32) in the 1L patient population, 68.2% in the 1L fit population and 84.6% in the 1L fit population who did not have venetoclax treatment extended beyond 1 year. MRD responses were consistent regardless of cytogenetic subgroups and clinical fitness status. MRD-negativity was reported in bone marrow assessment in 78.1% (25/32) of 1L patients.

<div style=\"page-break-after: always\"></div>

The efficacy outcomes (ORR and MRD negativity) were similar in all 1L group of patients analysed, including the 22 1L patients considered to be 'fit' and to have been potentially eligible to receive chemoimmunotherapy (FCR or BR) as treatment prior to study entry.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The pivotal trial CLL14 was a randomized, multicenter, open label, phase 3 study that evaluated the efficacy and safety of venclyxto in combination with obinutuzumab (VEN+G) versus obinutuzumab in combination with chlorambucil (GClb) for patients with previously untreated CLL with coexisting medical conditions (total Cumulative Illness Rating Scale [CIRS] score &gt; 6 or CLcr &lt; 70 mL/min, but not inferior to 30 mL/min). All the patients included required therapy (Binet stage C or symptomatic disease). Patients with Rich ter's transformation or any individual organ/system impairment score of 4 by CIRS were excluded. Since new treatment options were approved during the recruitment period, patients with TP53 deletion or mutation were enrolled at the investigator's discretion . Patients in the study were assessed for risk of TLS and received prophylaxis accordingly prior to obinutuzumab administration. All patients received obinutuzumab at 100 mg on Cycle 1 Day 1, followed by 900 mg which could have been administered on Day 1 or Day 2, then 1000 mg doses on Days 8 and 15 of Cycle 1, and on Day 1 of each subsequent cycle, for a total of 6 cycles. On Day 22 of Cycle 1, patients in the venetoclax + obinutuzumab arm began the 5-week venetoclax dose-titration schedule, continuing through Cycle 2 Day 28. Upon completion of the dose-titration schedule, patients continued venetoclax 400 mg once daily from Cycle 3 Day 1 until the last day of Cycle 12. Each cycle was 28 days. Patients randomised to the obinutuzumab + chlorambucil arm received 0.5 mg/kg oral chlorambucil on Day 1 and Day 15 of Cycles 1-12. Patients continued to be followed for disease progression and overall survival after completing therapy.

After a separate safety run-in, 432 patients were randomized 1:1. Cross-over was not allowed. All patients received obinutuzumab at 1000 mg on d1 (the first dose could be split as 100 mg and 900 mg on d1 and 2), and on d8 and 15 of cycle 1, and on d1 of each subsequent cycle, for a total of 6 cycles. Patients in the VEN+G arm began the 5-week venclyxto ramp-up schedule on d22 of cycle 1 and received venclyxto 400 mg once daily from cycle 3 d1 until the last day of cycle 12. Patients randomized to the GClb arm received 0.5 mg/kg oral chlorambucil on d1 and d15 of cycles 1 to 12. Each cycle was 28 days.

The primary endpoint was investigator-assessed PFS. The key secondary endpoints were IRC PFS, minimal residual disease negativity (allele-specific oligonucleotide polymerase-chain-reaction with a cutoff of 10 -4 ) in peripheral blood and bone marrow, overall and complete response, MRD negativity in patients with complete response in PB and marrow (all assessed 3 months after treatment completion), and OS. Other secondary endpoints included DOR, EFS and time to new antileukemic treatment.

Disease was assessed in all patients at baseline and at similar time points in both treatment groups during the trial, including an assessment of the response to therapy 3 months after the completion of treatment, with CR and PR defined in accordance with iwCLL 2008. After the completion of treatment, patients were followed for progression and safety every 3 months for 2 years, and then every 6 months. MRD PB was performed at baseline and at cycles 7, 9, and 12, and then every 3 months. In patients with a treatment response, minimal residual disease in bone marrow was assessed at cycle 9 and 3 months after completion of treatment.

An interim analysis was planned as per protocol to be performed after 110 progression events (65% of total planned events) had occurred. After IA data review (cut-off August 2018), IDMC recommended conducting the primary analysis of the primary and secondary endpoints.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

The baseline demographic and disease characteristics were similar between the study arms. The median age was 72 years (range: 41 to 89 years), 89% were white, 67% were male; 36% and 43% were Binet stage B and C, respectively and approximately half (49.8%) were experiencing B symptoms at baseline, with night sweats (43.5%) being the most frequent B symptom. The 88% of patients had ECOG performance status &lt;2. The median CIRS score was 8 (range: 0 to 28) and 58% of patients had CLcr &lt;70 mL/min. A 17p deletion was detected in 8% of patients, TP53 mutations in 7%, 11q deletion in 19%, and unmutated IgVH in 59.8%. The mutational status was unknown for 59 patients (27.3%) in the GClb arm and 45 (20.8%) in the VEN+G arm. Overall, the median time from first diagnosis of CLL to randomization was 2.5 years (0-20.4 years). TLS risk was categorized as low, medium or high and the risk categories were balanced between groups: 43 patients (20%) in the GClb arm and 48 (22.2%) in the VEN+G arm belonged to the high risk category). The majority of patients (66.2%) were considered as intermediate risk. In terms of prognosis, the CLL-IPI scores were similar for the two treatment arms; 60% in the GClb arm and 60.4% in the VEN+G arm had a high score.

Progression-free survival (PFS) was assessed by investigators and by an Independent Review Committee (IRC) using the International Workshop for Chronic Lymphocytic Leukemia (IWCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008).

At the interim analysis, all patients were off-treatment for about 17 months. The PFS data can be considered immature, as the number of events in the control arm was low, 35.6% (13.9% in the experimental arm). The HR for progression or death is 0.35 (0.23-0.53). From around month 23 and on, extensive censoring is observed in the KM curves; a KM plot of time in study (from randomization to data cut-off) has been provided. The time in study is similar between the treatment arms, with the majority of patients having a follow-up over 39 months.  The robustness of the primary efficacy analysis however is supported by sensitivity analyses related to the censoring mechanism for PFS, unstratified analyses, and subgroup analyses (including TP53 mutations, deletions or both; and unmutated IgVH ).

At end of treatment visit, 123 patients (56.9%) in the VEN+G arm had achieved bone marrow MRD negativity and 163 (75.5%) peripheral blood MRD negativity, compared with 37 patients (17.1%) and 76 patients (35.5%), respectively, in the GClb arm. Twelve months after the completion of treatment, MRD negativity rates in peripheral blood were 58% (126/216) in patients treated with VEN+G and 9% (20/216) in patients treated with GClb. In CR/CRi patients, the MRD-negativity rates at end of treatment were higher for VEN+G than for GClb: bone marrow 73 (33.8%) vs 23 (10.6%); peripheral blood: 91 (42.1%) vs 31 (14.4%). In the MURANO study (RR CLL), the MRD status was similar regardless of clinical response; for completeness, data on MRD in PR were presented for study CLL14 and are similar to MURANO findings.

In both arms of study CLL14, the patients who had reached PB MRD negativity at EOT had a longer duration of PFS compared with MRD positive patients. Dimier et al. published a model for predicting the effect of treatment on PFS using PB-MRD as a surrogate endpoint in treatment-naïve patients from studies CLL8, CLL10, and CLL11 (Blood. 2018 Mar 1;131(9):955-962). The model demonstrated a statistically significant relationship between treatment effect on PB-MRD and treatment effect on PFS. As the difference between treatment arms in PB-MRD response rates increased, a reduction in the risk of progression or death was observed; for each unit increase in the (log) ratio of MRD -  rates between arms, the log of the PFS hazard ratio decreased by -0.188 (95% CI -0.321 to -0.055). A similar approach, i.e. evaluation of the relationship between treatment effect on PB-MRD and treatment effect on PFS for study CLL14 was presented by the MAH.  The available PFS and MRD data support an effect across cytogenetic subgroups and mutational status. The ORR (CR+CRi+PR) was 183 (84.7%) for VEN+G and 154 (71.3%) for GClb. The complete response rate (CR+CRi) was 107 (49.5%) vs 50 (23.1%).

At the time of analysis, median overall survival had not been reached, with fewer than 10% of patients in the study experiencing an event. The median duration of follow-up for OS was 29 months.

<div style=\"page-break-after: always\"></div>

The PFS benefit with venetoclax + obinutuzumab versus obinutuzumab + chlorambucil treatment was observed across the following subgroups: sex; age; Binet stage at screening; estimated CrCL; del(17p)/ TP53 mutation; IgVH mutational status.

Although exploratory, the efficacy outcomes from study GP28331 (a 32 first-line patient subgroup) support the findings of the pivotal study CLL14. Noteworthy, the trial included 22 1L ¨fit¨ patients, who otherwise could have received a fludarabine-based regimen.

At an updated efficacy analysis (data cut-off date 23 August 2019 and median follow-up of 40 months), the median PFS had not been reached in the venetoclax + obinutuzumab arm and was 35.6 months [95% CI: 33.7,40.7] in the obinutuzumab + chlorambucil arm with a HR of 0.31 [95% CI: 0.22, 0.44]. The 36month PFS estimate in the venetoclax + obinutuzumab arm was 81.9% [95% CI: 76.5, 87.3] and in the obinutuzumab + chlorambucil arm was 49.5% [95% CI: 42.4, 56.6].

The applicant is seeking an indication for first-line treatment of CLL regardless of fitness, including suitability for FCR. While the patients included in study CLL14, with a median age of 72 and a median CIRS score of 8, might be regarded as representative for most CLL patients, the comparator as well as the inclusion criteria exclude more fit patients. However, based on the precedent set for Imbruvica (ibrutinib), the extrapolation of efficacy also to younger and more fit patients is considered acceptable. This is since the safety profile in such patients is not anticipated to be less favourable; furthermore, the effect size, although not directly compared with FCR, is considered sufficient to make venetoclax + obinutuzumab a reasonable first-line treatment alternative, where the differential safety profile comparted to chemotherapy is notable. The inclusion criteria for the pivotal study (i.e. patients with coexisting conditions) are reflected in section 5.1 of the SPC and study GP28331 did include a small number of fit patients.

## 2.4.4. Conclusions on the clinical efficacy

Venclyxto and obinutuzumab combination followed by venclyxto monotherapy offer longer progressionfree survival compared to chlorambucil and obinituzumab in a first-line CLL population that are either older than 65 years of age or have co-morbidities. The relevance of the efficacy demonstration can be extrapolated to more fit patients with CLL.

## 2.5. Clinical safety

## Introduction

## Patient exposure

VEN+G was completed by 159 of the 203 who received both agents while VEN single agent treatment was completed by 166 of the 198 patients who started the single-agent period. The median duration of exposure to venetoclax, from first venetoclax dose, was 315 days (10.5 months). After reaching the target dose, the median dose intensity for venetoclax was 97.5% (range: 14%-100%).

<div style=\"page-break-after: always\"></div>

## Adverse events

Overview of all AEs (safety population)

<!-- image -->

|                                                            | GCllb (N=214)   |             | VEN+G (N=212) (N=426)   | All Patients   |
|------------------------------------------------------------|-----------------|-------------|-------------------------|----------------|
| Total mumber of patients with at least one AE              | 213(99.51)      |             | 200(94.38)              | 413(96.91)     |
| Total mmber of E                                           | 2074            |             | 2448                    | 4522           |
| Total mmber of deaths                                      | 16(7.58)        |             | 20(9.48)                | 36(8.51)       |
| Total mmrer of patients withdrawm from study due to an AE  | 1(0.51)         |             | 4(1.98)                 | 5(1.24)        |
| Total mmber patients with at least one                     |                 |             |                         |                |
| HE with fatal outeome                                      | 8 (3.74]        | 16          | (7.58)                  | 24 (5.68)      |
| Serious HE                                                 | 06 (42.18)      | 104         | (49.18)                 | 194 (45.54)    |
| Serious HE leading to withdrawel from sny treatment        | 18 8.48)        | 14 11       | 6.61                    | 32 (AS'L) 11   |
| Serious HE leading to withdkawal fnom Venetoclaw           | D               |             | 5.241                   | 2.681          |
| Berious HE leading t.o interruption from any treatment     | 29              | (13.68) 48  | (22.61)                 | 77 (18.1) 2    |
| Serious HE leading to dose rednction from any tneatment    |                 | 0.51] 1     | (0.51)                  | (0.58)         |
| Related Serious AE                                         | 56              | (26.24) 56  | (26.48)                 | 112 [26.38)    |
| HE leading to withdrawal from cny treatment                | 33              | (15.48) 34  | (16.01)                 | 67 (15.74)     |
| E Leading to withdrawal from Wenetoclen                    |                 | 27          | (12.74)                 | 27 (48'9]      |
| HE leading to dose internuption fnom any treatment         | 146             | (68.24] 156 | (73.61)                 | 302 (70.94)    |
| AE leading to dose rednction from eny treatment            | 18              | 8.4) 44     | (20.88)                 | 62 (14.68)     |
| Related AE                                                 | 200             | (93.54) 190 | (89.61)                 | 390 (91.54)    |
| Related HE leading to withdrawel from eny treatment        | 25              | (11.78) 29  | (13.74)                 | 54 (12.78)     |
| Related AE leading to withdrawal from Venetoclam           | 0               | 23          | (10.68)                 | 23 (5.48]      |
| Related AE leading to dose interruption from any treatment | 135             | (63.18) 147 | (69.38)                 | 282 (66.24)    |
| Related HE leading to dose reduetion from any tneatment    | 18              | 8.481 39    | (18.48)                 | 57 (13.48)     |
| Grade 3.4 HE (at greatest intensity)                       | 157             | (73.48) 151 | (71.28)                 | 308 [72.38]    |
| Grade 3,4 HE                                               | 164             | (76.64) 167 | (78.88)                 | 331 (77.78)    |

All-cause mortality: 9.3% VEN+G vs 7.9% GClb.

Adverse Events with a reporting rate of at least 10%

| MedlRA Preferred Term                                                                      | GC1h (=214)                            | VEN+G (M-212)                                                                        | All Patients (N=426]                                                              |
|--------------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Total nimber of patients with at least one adverse event Total mmber of events Neutropenia | 213(99.58) 2074 122 (57.0) 110 (51.41) | 200(94.3) 2448 122 (57.58) 95 (44.88) 51 (24.18) 59 [27.88] 40 (18.98) 48 [22.68) 35 | 413(96.9) 4522 244 (57.31) 205 101 [23.74) 91 [21.48] 86 [20.28) 81 19.08 75 17.6 |
| Infusionrelatadreaction                                                                    |                                        |                                                                                      |                                                                                   |
| Threnbocytopenin                                                                           | 50 (23.48)                             |                                                                                      |                                                                                   |
| Diarrhoea                                                                                  | 22 (15.08                              |                                                                                      |                                                                                   |
|                                                                                            | 46 (21.58)                             |                                                                                      |                                                                                   |
| Bwrenir                                                                                    | 33 (15.48)                             |                                                                                      |                                                                                   |
| Anremi:                                                                                    | 40 (18.78)                             | (16.58                                                                               |                                                                                   |
| Fatigue                                                                                    | 30 RO'FT                               | 32 (15.18)                                                                           | 62 [14.68]                                                                        |
| Cough                                                                                      | 25 (11.78)                             | (16.08)                                                                              | 59 (13.8H)                                                                        |
| Constipntion                                                                               | 1.9 6*8]                               | 28 (13.2H)                                                                           | 47 (11.08                                                                         |
| Herdhche                                                                                   | 21 49'6]                               | 24 (11.38)                                                                           | 45 [10.6]                                                                         |

In the VEN+G arm, the most frequently reported (&gt;5%) venetoclax-related AEs were neutropenia (102 patients [48.1%]) and thrombocytopenia (23 patients [10.8%]); diarrhoea (31 patients [14.6%]) and nausea (20 patients [9.4%]); and fatigue (13 patients [6.1%]).

AEs by severity (CTCAE)

<!-- image -->

| Wad0RASwstem CIF4A WedDRA Pne Term   | GClh (F214)                                                   | VEN+G (N-212)                                           | Hll Patients (NF426)                                         |
|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|
| ·Any aduerse events                  | 213 (99.58) 20 (4.78) 38 117.88) 88 (41.18) 69 (32.24) [3.78] | 200(94.38) 日 （3.8） 226 (11.88) 146*18) [36.34) 16 (7.58 | 413 196.9 18 (4.28 63 (14.88) 162 (38.08) 146 (34.38 24(5.68 |

Grade 3-4 PTs reported with an incidence at least 2% higher in the VEN+G arm were neutropenia (112 patients [52.8%] vs 103 [48.1%] in the GClb arm), hyperglycemia (8 [3.8%] vs 3 [1.4%], respectively), diarrhea (9 [4.2%] compared with 1 [0.5%], respectively) and hypertension (6 [2.8%] compared with 1 [0.5%], respectively).

<div style=\"page-break-after: always\"></div>

## Dose reduction or interruption

## Venetoclax

- Interruption: 334 AEs leading to dose interruption of venetoclax were reported in 121 patients (57.1%). The most common AE that resulted in dose interruption of venetoclax was neutropenia (86 patients [40.6%]). No other AE leading to venetoclax dose interruption was reported in more than 5% of the patients in the VEN+G arm.
- Reduction: dose reductions due to AEs were reported in 43 patients (20.3%). The most common AEs (reported in 3 or more patients) that resulted in dose reduction of venetoclax were neutropenia (28 patients [13.2%]), neutrophil count decreased (4 patients [1.9%]), thrombocytopenia (4 patients [1.9%]).

## Obinutuzumab

- Interruption: overall, 247 and 259 AEs leading to obinutuzumab dose interruption, respectively, were reported in 112 patients (52.3%) in the GClb arm and 119 (56.1%) in the VEN+G arm. The most common AEs that resulted in dose interruption of obinutuzumab were neutropenia (49 patients [22.9%] in the GClb arm and 56 [26.4%] in the VEN+G arm) and infusion-related reaction (57 patients [26.6%] and 50 [23.6%], respectively). No other AE leading to obinutuzumab dose interruption was reported in more than 5% of patients in either arm.
- Reduction: obinutuzumab dose reductions were not allowed according to the protocol, but were reported in 2 patients (0.9%) in the GClb arm (due to AEs of IRR and neutropenia) and 3 (1.4%) in the VEN+G arm (due to AEs of IRR, nausea, fatigue and neutrophil count decreased).

## Chlorambucil

- Interruption: 266 AEs leading to dose interruption of chlorambucil were reported in 121 patients (56.5%). The most common AEs that resulted in dose interruption of chlorambucil were neutropenia (83 patients [38.8%]) and thrombocytopenia (12 patients [5.6%]). No other event was reported in more than 5% of the patients.
- Reduction: Chlorambucil dose reductions due to AEs were reported in 17 patients (7.9%). The most common AEs (reported in 2 or more patients) that resulted in dose reduction of chlorambucil were neutropenia (13 patients [6.1%]), neutrophil count decreased (2 patients [0.9%]), and thrombocytopenia (2 patients [0.9%]).

## Discontinuation due to adverse events

Patients were withdrawn from venetoclax when toxicity could not be managed by dose interruption and dose reduction: 27 patients (12.7%) withdrew from venetoclax treatment due to AEs. The most common AEs that resulted in withdrawal of venetoclax were neutropenia (5 patients [2.4%]), sepsis (2 patients [0.9%]), and asthenia (2 patients [0.9%]).

The percentage of patients who withdrew from obinutuzumab treatment was balanced between treatment arms (16 patients [7.5%] in the GClb arm and 15 [7.1%] in the VEN+G arm). The only AEs reported more than once in either treatment arm that resulted in withdrawal of obinutuzumab were neutropenia (2 patients [0.9%] in the GClb arm and 1 [0.5%] in the VEN+G arm), thrombocytopenia (1 patient [0.5%] and 2 [0.9%], respectively), anaemia (2 patients [0.9%] and none, respectively), and infusion-related reaction (2 patients [0.9%] in both arms).

Thirty-one patients (14.5%) withdrew from chlorambucil because of an AE. The most common AEs that resulted in withdrawal of chlorambucil were neutropenia (5 patients [2.3%]), neutrophil count decreased (2 patients [0.9%]), and infusion-related reaction (2 patients [0.9%]).

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest (AESI)

## Neutropenia, gr 3-4

<!-- image -->

| MadlRA Systen Orgen Cles9 MedbRa.Preferred Tem           | GCllb (N=214)   | VEN+G (N=212)   | All Patients (N=426)   |
|----------------------------------------------------------|-----------------|-----------------|------------------------|
| Total nmiber of patients with at least one adverse event | 112 (52.3)      | 119(56.1)       | 231(54.24)             |
| Overalltotalnmlerofevents                                | 250             | 327             | 577                    |
| Bloodend lymphatic System disorders                      |                 |                 |                        |
| Totalmmberofpatientswithatlesst oneadverseevent          | 103(48.1)       | 112 (52.88)     | 215 (50.58)            |
| Totalmumber of events                                    | 224             | 306             | 530                    |
| Neutropenin                                              | 103(48.1)       | 112（52.8)       | 215(50.5)              |
| Inwestigations                                           |                 |                 |                        |
| Totalmumberofpatients withatlerstoneadverseeuent         | 10(4.78)        | 9(4.2)          | 19(4.5)                |
| Totalmmberofevents                                       | 26              | 21              | 47                     |
| Neutrophil count decrersed                               | 10(4.74)        | 9(4.24)         | 19(4.5)                |

## Thrombocytopenia, gr 3-4

| WedlRA System Orgen Ciaus MedDRA Preferred Tem                                                                                        | (N=214)               | VEN+G (N=212)         | All Patients (N=426)   |
|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------|------------------------|
| Total mmber of patients with at least one adverse event                                                                               | 33(15.4)              | 32(15.1#)             | 65 (15.3)              |
| Ouerall total number of events                                                                                                        | 43                    | 51                    | 6                      |
| Blood and lymphatic system disorders Total number of patients with at lesst one adverse event Total.mimber of ewents Thrombocytopenia | 32(15.0) 42 32 (15.0) | 29(13.7) 47 29(13.7#) | 61(14.3) 89 61 (14.3)  |
| Investigations Total mumber of patients with at lesst one adverse evcht Totalnmber of events Plateletcoumtdecrerued                   | 1（0.5） 1 1(0.5)       | 4(1.9） 4(1.9）         | 5(1.2) 5 5(1.2)        |

<div style=\"page-break-after: always\"></div>

## Infections &gt; grade 3

| Med0Ra System Orgen Ciess MadDRA Preferredl Tem                 | GC1b (N=214)                | VEN+G (N=212)               | All Patients (N=426)   |
|-----------------------------------------------------------------|-----------------------------|-----------------------------|------------------------|
| Total nmber of patients with at least one adverse event         | 35(16.48)                   | 41(19.3)                    | 76 (17.84)             |
| Ouerali total munber of events                                  | 51                          | 58                          | 109                    |
| Infections end infestationg                                     |                             |                             |                        |
| Total mumber of patients with at lesst one adverse euent        | 35 (Hb*91)                  | 41 (19.3)                   | 76 (17.8)              |
| Total mmber of events                                           | 51                          | 58                          | 109                    |
| Pmeumonia                                                       | 4.211                       | 6 4.24)                     | 18 4.24)               |
| Sepsis                                                          | 0.911                       | 3.311                       | 2.11                   |
| Bronchitis                                                      | 9.98                        | 9.98                        | 0.911                  |
| Drinary tract infeetion                                         | 11.1                        | 0.581                       | 0.981                  |
| Cellnlitis                                                      | 9.511                       | 146*0                       | 3 9.711                |
| Infection                                                       | 9.531                       | 9.981                       | 3 9.731                |
| Respiratory tract infection                                     | 0.581                       | 0.981                       | 0.711                  |
| Septic shocl                                                    | 0.941                       | 0.54)                       | 3 0.741                |
| Upper respiratory tract infection                               | 9.931                       | 0.54)                       | 0.731                  |
| Urosepsis                                                       | 0.511                       | 0.981                       | 3 0.781                |
| Atypical pneumonia                                              | 0.511                       | 9.581                       | 0.511                  |
| Detice related infection                                        |                             | (66*0                       | 0.511                  |
| Erysipelas                                                      | 0.511                       | 0.541                       | 0.511                  |
| Gaitroenteritis                                                 | 186.8                       |                             | NNNN 0.511             |
| Hepatitis viral                                                 | 186.9 0.581                 | (0.58)                      | 0.511 0.511            |
| Infectious pleural effusion                                     |                             |                             | 0.511                  |
| Lung infection Bmetmocygtis jirovecii pnaumonia                 | 0.511 8.58                  | 9.511                       | 0.511                  |
|                                                                 | 0.541                       | 189.0                       | 0.511                  |
| Byelonephritis                                                  |                             | 0.531                       | NNN                    |
| Abscess' 1inb                                                   |                             | 0.54)                       | 1 0.21                 |
| Amoebiasis                                                      |                             | (49'0)                      | 1 9.281                |
| Bronchiolitis                                                   | 0.511                       |                             | 1 0.211 0.211          |
| Bronchopulmonery aspergillosis Candida infection                | 0.541                       | (HS'0]                      | 0.241                  |
|                                                                 | HAHNNHHOHNNHAHHOOHHOHHOOOOA |                             |                        |
| Chronic sinuitis                                                | 0.511                       |                             | 1 0.21                 |
| Eenema infected                                                 | 0.58)                       | 0.581                       | 0.211                  |
| Endocarditis Enteritis infectious                               |                             | 0.581                       | 0.211 0.211            |
| Gastrointegtinal infection                                      |                             | 0.511                       | 0.211                  |
|                                                                 |                             |                             | 0.211                  |
| Hepatitis E                                                     | (69'0)                      | 0.511                       |                        |
| Heipes soster                                                   | 0.511                       |                             | 0.241                  |
| Infective exacerbation of chronic cbstnuctive airweys disesse   | 0.54)                       |                             | ==== 0.281 0.211       |
| Influensa. Listeriosis                                          |                             | (0.51)                      | 0.21                   |
| Localiged infeation                                             | (H6'0]                      |                             | 0.2+1                  |
| Lower respiratory tract infection                               |                             | 149:0                       | 0.231                  |
| Miscle sbsoess                                                  |                             | 189.0                       | 0.211                  |
| Ophthalmie herpes soster                                        |                             | 0.511                       | 1 9.211                |
| Bheumonia fmgal                                                 |                             | 0.511                       | 1 0.241                |
| Fmeumonia hsemephiluu                                           | 0.511                       |                             | 0.211                  |
|                                                                 |                             |                             | 0.211                  |
| Bmeumonie, respiiatory eymcytial viral Pseudomembranous colitis | 0.511                       |                             | 0.241                  |
| Sinusitis                                                       |                             | 0.541 0.581                 | == 0.211               |
|                                                                 |                             | 0.511                       | 0.211                  |
| Shin infection                                                  |                             | OPPOOOPPPPPOOPPPPOPOO 186.9 | 0.23                   |
| Soft tissue infection                                           |                             | 0.511                       | 0.241                  |
| Staphylocoocal infection                                        | 0.511                       |                             | 0.211                  |
| Staphylococcal sepsis                                           | 186.9                       |                             | 0.211                  |
| Tooth sbgce99                                                   | 0.581                       |                             | 9.311                  |
| Tooth infeetion                                                 |                             | 0.581                       | 0.211                  |
| Vericella sogter vins infection                                 | POOFHFOOOOOPHOOOOPOPH       | 0.54)                       | 0.211                  |
| Wound infection fungal                                          | (0.58)                      |                             | 0.241                  |

## Second primary malignancies

The incidence of second primary malignancies was 22 patients [10.3%] in the GClb arm compared with 29 [13.7%] in the VEN+G arm.

## TLS

There were 8 patients with AEs reported as TLS by the investigator, 5 (2.3%) in the GClb arm and 3 (1.4%) in the VEN+G arm. All AEs in the VEN+G arm occurred prior to the first dose of venetoclax and were associated with obinutuzumab treatment.

## Richter's transformation

One patient in the GClb arm (timing not known) and 2 in the VEN+G arm (within 2 months of starting tx) developed Richter's transformation. All 3 transformations were to DLBCL.

## Infusion-related reactions grade 3-4 (obinutuzumab)

The incidence of gr 3-4 IRR was balanced between treatment arms: 10.7% in the GClb arm vs 11.8% in the VEN+G arm. No fatal IRRs were reported. Treatment for IRR was administered to 19 patients in each arm; 13 patients in each arm required interruption; 1 had an obinutuzumab dose reduction. Obinutuzumab was withdrawn due to IRRs in 2 patients in the GClb arm and 2 in the VEN+G arm. All but 2 patients recovered with sequelae. One patient was recovering at the time of the cut-off.

<div style=\"page-break-after: always\"></div>

## Serious adverse events

| MedDRA System Orgen Class MadDRA'Preferred Tem                     | GClb (N=214)   | TEN+G (N=212)   | Hll Patients (N=426)   |
|--------------------------------------------------------------------|----------------|-----------------|------------------------|
| Total number of patients with at least one edverse euenb           | 90(42.14)      | 104(49.14)      | 194(45.51)             |
| Overall total mumiber of events                                    | 179            | 202             | 381                    |
| Infections end infestationg                                        |                |                 |                        |
| Total mmbar of patients with at least one sdverse event            | 30 (14.04)     | 40 (18.98)      | 70 [16.48)             |
| Total mmber of events                                              | 44             | 56              | 100                    |
| Bmeumonia                                                          | 4.211          | 10 [ 4.741      | 19 4.511               |
| Bepsis                                                             | 9.911          | 6 2.811         | 8 1.911                |
| Bronchitis                                                         | 0.941          | 2 0.981         | 4 0.981                |
| Infection                                                          | NONH (0.94)    | 0.981           | 4 0.911                |
| Cellnlitis                                                         |                | 1.48            | 3 0.731                |
| Influensa                                                          | 0.981          | 0.531           | 3 0.711                |
| Respiratory tract infection                                        | 0.541          | 136.0           | 3 0.741                |
| Septie shock                                                       | 2 0.911        | 0.511           | 3 0.741                |
| Urosepsis                                                          | 0.511          | 0.981           | 3 0.741                |
| Device related infection                                           |                | 0.91)           | 0.511                  |
| Gagtroenteritis                                                    | (0.98)         |                 | 0.511                  |
| Lumg infection                                                     | 2 (0.94)       | HNNOO           | 2 (0.51)               |
| Injury! poisoning and procedural conplicationg                     |                |                 |                        |
| Total1 mmber of patients with at least one adverse ewent           | 22(10.3)       | 16( 7.51)       | 3818.94)               |
| Total mmber of events                                              | 22             | 19              | 41                     |
| Infusion relatad reaction                                          | 13 (6.181      | 9 [4.28]        | 22 15.211              |
| Linb injury                                                        | 2 (0.94)       |                 | 10.58]                 |
| Blood snd lymphatic system digorderg                               |                |                 |                        |
| Total mumber of patients with at least one adverse event           | 17 (7.94)      | 19 (9.04)       | 361 8.51)              |
| Total mmber of events                                              | 20             | 24              | 44                     |
| Fehrile neutropenia                                                | 8 [3.78]       | 11 [ 5.211      | 19                     |
| Thrombocytopenia                                                   | 2.381          | 1 0.981         | 7 1.681                |
| Neutropenie.                                                       | 1 181.0        | 1.48            | 4 146.0                |
| Anaemia.                                                           | 1 0.511        | 0.981           | 3 0.741                |
| Neoplagmg benign, malignent snd wspecified (inel cyats and polyps) |                |                 |                        |
| Total mmber of patients with at least one sdverse cuent            | 12 (5.61)      | 15 ( 7.18)      | 27(6.31)               |
| Total mmber of events                                              | 13             | 15              | 28                     |
| Sgurmous cell carcinome of shin                                    | 3 (1.48)       | 146:61          | 5 (1.2)                |
| Prostate csncer                                                    | 0              | 2 (0.98)        | 2 (0.5+]               |
| Ganeral digorderg end administration site conditiong               |                |                 |                        |
| Total mmber of patients with at least one sdverse event            | 6 (.4.24)      | 12(5.78)        | 21 (4.94)              |
| Total mmber of ewents                                              | 10             | 13              | 23                     |
| Byrenia                                                            | [3.3]          | 8 (3.88]        | 15 ( 3.51)             |
| Respiratory. thoraeie end madisytinal disorders                    |                |                 |                        |
| Total mmber of patientg with at least one edverse event            | 6 (4.24)       | 12 15.78]       | 21 [4.98]              |
| Total mmber of events                                              | 10             | 20              | 30                     |
| Chronic obstructive pulmonary disease Pleural effusion             | 0.911          | 6.511           | 1.211 6.341            |
| Dyspnoea                                                           | NNO 0.941      | 0.981           | 0.511                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

The frequency of patients with SAEs was numerically higher in the experimental arm (104 patients [49.1%]) compared with the GClb arm (90 patients [42.1%]).

The SOC with the most SAEs was Infections and infestations , with a numerically higher incidence in the VEN+G arm (40 patients [18.9%]) compared with the GClb arm (30 patients [14.0%]). By individual PT within this SOC, the largest difference occurred for sepsis (6 patients [2.8%] in the VEN+G arm and 2 patients [0.9%] in the GClb arm).

SAEs in the Blood and lymphatic system disorders SOC were reported in 17 patients (7.9%) in the GClb arm and 19 (9%) in the VEN+G arm. The 3 most frequent AEs in this SOC were febrile neutropenia (reported in 8 patients [3.7%] and 11 [5.2%], respectively), thrombocytopenia (5 patients [2.3%] and 2 [0.9%], respectively), and neutropenia (1 patient [0.5%] and 3 [1.4%], respectively).

SAEs in the Neoplasms benign, malignant and unspecified SOC were reported in 12 patients (5.6%) in the GClb arm and 15 (7.1%) in the VEN+G arm.

The most frequently reported individual PTs were infusion-related reaction, 13 patients (6.1%) in the GClb arm and 9 (4.2%) in the VEN+G arm; pneumonia (9 [4.2%] and 10 [4.7%], respectively); febrile neutropenia (8 [3.7%] and 11 [5.2%], respectively) and pyrexia (7 [3.3%] and 8 [3.8%], respectively). The only SAE by grouped PT occurring in more than 5% of the patients in either arm was pneumonia (11 patients [5.1%] in the GClb arm and 13 [6.1%] in the VEN+G arm).

<div style=\"page-break-after: always\"></div>

## Deaths

| PeriodinWhichDeathOccurred:                                    | NumberofPatients   | NumberofPatients   |
|----------------------------------------------------------------|--------------------|--------------------|
|                                                                | GCIb               | VEN+G              |
| Totalnumberduringstudy(safety-evaluable)                       | 16                 | 20                 |
| Any time during study(overall)                                 |                    |                    |
| Disease progression                                            | 5                  | 3                  |
| Fatal AEs                                                      | 8                  | 16                 |
| Other                                                          | 3                  | 1                  |
| During treatment(within 28 days after last dose of study drug) |                    |                    |
| Disease proqression                                            | 0                  | 1                  |
| Fatal AEs                                                      | 3                  | 4                  |
| Other                                                          | 0                  | 0                  |
| Total duringtreatment                                          | 3                  | 5                  |
| Aftertreatment(after29daysafter thelastdoseofstudy drug)       |                    |                    |
| Disease progression                                            | 5                  | 2                  |
| Fatal AEs                                                      | 5                  | 12                 |
| Other?                                                         | 3                  | 1                  |
| Totalaftertreatment                                            | 13                 | 15                 |

<!-- image -->

During the treatment period (or within 28 days of last study drug) there were 3 deaths in the GClb arm and 5 patients in the VEN+G arm. After the end of the study treatment period: 13 in the GClb arm and 15 in the VEN+G arm. Of the 13 post-treatment deaths in the GClb arm, 5 were due to disease progression, 5 t o fatal AEs, and 3 were attributed to 'other' causes (respiratory sepsis, sepsis and unknown). Of the 15 post-treatment deaths in the VEN+G arm, 2 deaths were attributed to disease progression, 12 to fatal AEs and 1 to 'other' causes (reported as natural cardiac death). 'Other' causes refer to deaths that were reported as a reason for study discontinuation; after patients had discontinued study treatment for other

<div style=\"page-break-after: always\"></div>

reasons (i.e. disease progression or discontinued due to another AE).

## Fatal AEs

The frequency of fatal AEs was numerically higher in the VEN+G arm (n=16 [7.5%]) than in the GClb arm (n=8 [3.7%]). The most frequently reported AE leading to death was sepsis (1 patient in the GClb arm and 5 patients in the VEN+G arm). Cardiac arrest was reported in 1 patient in each arm.

Of the 16 patients who experienced Grade 5 AEs in the VEN+G arm, 2 patients (myelodysplastic syndrome and pneumonia fungal) discontinued obinutuzumab prior to receiving the first administration of venetoclax. In both cases, the investigator attributed a causal relationship to obinutuzumab. The other 3 fatal events with onset during the treatment period were sepsis (2 patients) and infection (1 patient). The onset of the remaining 11 fatal AEs occurred in the posttreatment period, that is, 29 days or more after the last study drug administration: one case was attributed to venetoclax.

In the GClb arm, of 8 patients with fatal AEs, 4 had onset during the treatment period, and 4 had onset in the post-treatment period.

- Fatal infections

In the experimental arm, 8 patients experienced fatal infection; of these, one did not receive venetoclax. In 4 patients, the fatal AEs occurred during the treatment period. One of them had Richter's transformation after event onset and died after salvage treatment with RCHOP and allogeneic stem cell transplant. In the other 4 patients, onset of the fatal events was after the end of the treatment period: onset 73, 156, 235 and 346 days after the last dose of venetoclax, respectively. One of these patients died after diagnosis and treatment of T-cell lymphoma (with CHOP therapy).

In the GClb arm, 3 patients experienced fatal events of infection, all of them with onset during the treatment period.

- Cardiovascular deaths

Four patients in the VEN+G arm and 1 patient in the GClb arm experienced fatal cardiovascular AEs. All of these AEs after the treatment period and all patients had a relevant medical history.

- Deaths due to second primary malignancies

<div style=\"page-break-after: always\"></div>

## Description of Fatal and Second Primary Malignancies

<!-- image -->

## Laboratory findings

Grade 4 laboratory abnormalities developing in ≥2% of patients treated with VEN+G included neutropenia (32%), leukopenia and lymphopenia (10%), thrombocytopenia (8%), hypocalcaemia (8%), hyperuricemia (7%), blood creatinine increased (3%), hypercalcemia (3%), and hypokalaemia (2%).

## Post-marketing experience

No additional safety signals have been identified based on post-marketing data of venetoclax for the treatment of patients with CLL (from Periodic Safety Update Report for Venetoclax dated 3 August 2018). Between the international birth date (11 April 2016) and 04 June 2018, the estimated cumulative patient exposure from company-sponsored interventional clinical trials for venetoclax is 3,505 patients. The estimated cumulative post-marketing patient exposure since first approval is 3,244.7 patient-treatment

<div style=\"page-break-after: always\"></div>

years. The MAH continues to actively monitor safety as part of the ongoing global pharmacovigilance program.

## 2.5.1. Discussion on clinical safety

A total of 426 patients were treated (212 with VEN+G, 214 with GClb). The median duration of exposure to venclyxto was 10.5 months (range: 0 to 13.5 months). The median number of cycles was 6 for obinutuzumab and 12 for chlorambucil.

In the VEN+G arm, fatal adverse reactions that occurred in the absence of disease progression and with onset within 28 days of the last study treatment were reported in 4/212 of patients vs. 2 /216 in GClb arm (all infections). Serious adverse reactions were reported in 49% of patients in the VEN+G arm and 42% in the GClb arm.

In the VEN+G arm, adverse reactions led to treatment discontinuation in 16% of patients (15.4 in GClb), dose reduction in 21% (8.4% in GClb), and dose interruption in 74% (68% in GClb). In the VEN+G arm, neutropenia led to dose interruption of venclyxto in 41% of patients, reduction in 13%, and discontinuation in 2%.

During treatment with single agent venclyxto after completion of VEN+G combination treatment, the most common all grade adverse reaction (≥10% patients) reported was neutropenia (26%). The most common grade ≥3 adverse reactions (≥2% patients) were neutropenia (23%) and anaemia (2%).

An analysis of gr≥3 SAEs in order to explore a possible relationship between organ/system morbidities at baseline and the risk of severe toxicity events in study CLL14 did not reveal any clear relationship.

Grade 3 or 4 neutropenia has been reported in patients treated with venetoclax in combination studies with rituximab or obinutuzumab and in monotherapy studies (see section 4.8). Complete blood counts should be monitored throughout the treatment period. Dose interruptions or reductions are recommended for patients with severe neutropenia (see section 4.2).

Serious infections, including sepsis with fatal outcome, have been reported (see section 4.8). Monitoring of any signs and symptoms of infection is required. Suspected infections are to receive prompt treatment, including antimicrobials and dose interruption or reduction as appropriate (see section 4.2).

Dosage reductions due to adverse reactions occurred in 21% of patients treated with the combination of venetoclax and obinutuzumab in the CLL14 study

Deaths due to infection occurred in 1.9% of patients while on treatment and 1.9% of patients following treatment discontinuation.

Dose interruptions due to adverse reactions occurred in 74% of patients treated with the combination of venetoclax and obinutuzumab in the CLL14 study In the open-label, randomised phase 3 study (CLL14), the incidence of TLS was 1.4% (3/212) in patients treated with venetoclax + obinutuzumab. All three events of TLS resolved and did not lead to withdrawal from the study. Obinutuzumab administration was delayed in two cases in response to the TLS events.

## 2.5.2. Conclusions on clinical safety

No new safety concerns for venclyxto were identified during in the pivotal and the supportive trial, respectively. However, the proposed regimen is not less toxic than chlorambucil and obinutuzumab, the current standard of care in previously untreated CLL patients with coexisting conditions. Neutropenia, leading to severe infections, dominates the safety profile of the venclyxto and obinutuzumab combination. A higher rate of fatal infections was observed for patients randomized to VEN+G. Section 4.4 of the SPC

<div style=\"page-break-after: always\"></div>

was amended to emphasize that neutropenic patients require constant monitoring for prompt identification of infection and aggressive treatment.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version 5.1 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 5.4 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 5.4 with the following content:

Table 28. Safery Concerns

| Summaryof Safety Conccrns   | Summaryof Safety Conccrns                                                                                                                    |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks  | Tumor lysis syndrome Neutropenia Serious infection                                                                                           |
| Important potential risks   | Embryofetal toxicity Medication error Richter's transformation Second primary malignancy Toxicity in patients with severe hepatic impairment |
| Missing information         | Safety in severe renal impairment Safety in long-term exposure (> 12 months)                                                                 |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

## Table 29.On-Going and Planned Additional Pharmacovigilance Activities

| Study Name Status                                                                                                                                                                                                                                                    | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                                                                         | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               |
| Not applicable                                                                                                                                                                                                                                                       | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                           | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Not applicable                                                                                                                                                                                                                                                       | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Study M14-032 A Phase 2 Open- label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukaemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy                                               | Assess the efficacy and safety of venetoclax monotherapy in subjects with CLL relapsed after or refractory to treatment with ibrutinib or idelalisib                                                                       | Safety in long-term exposure (> 12 months) of venetoclax Second primary malignancy and Richter's transformation                                                                                                            | Interim CSR Final CSR                                                                                                                                                                                                      | Report submitted March 2018 December 2022                                                                                                                                                                                  |
| Study GO28667 (MURANO) Multicenter, Phase III, Open- Label, Randomised Study in Relapsed / Refractory Patients with Chronic Lymphocytic Leukaemia to Evaluate the Benefit of venetoclax (GDC-0199/ ABT-199) Plus Rituximab Compared with Bendamustine Plus Rituximab | Evaluate the safety and efficacy of venetoclax and rituximab compared with BR in subjects with R/R CLL                                                                                                                     | Overall safety profile (provide comparator data) Richter's transformation and secondary primary malignancy                                                                                                                 | Primary analysis and interim CSR completed Final CSR                                                                                                                                                                       | December 2017 December 2022                                                                                                                                                                                                |
| Study M13-982 A Phase 2 Open- Label Study of the                                                                                                                                                                                                                     | Evaluate the safety and efficacy of venetoclax monotherapy in subjects with R/R CLL in the                                                                                                                                 | Safety in long-term exposure (> 12 months) of venetoclax                                                                                                                                                                   | Interim CSR                                                                                                                                                                                                                | Report submitted June 2018                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Study Name Status                                                                                                                                                                  | Summary of Objectives                                                                                                                                                 | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                     | Milestones               | Due Dates                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------|
| Efficacy of ABT- 199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukaemia Harboring the 17p Deletion                                                              | presence of 17p del or TP53 mutations                                                                                                                                 | Second primary malignancy and Richter's transformation                                                                                                                                                                                                                                                                                                        | Final CSR                | May 2021                                                               |
| Ongoing                                                                                                                                                                            |                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                               |                          |                                                                        |
| Study M12-175 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma | Assess the safety profile; characterize PK; determine MTD, RPTD, and lead-in period regimen of venetoclax monotherapy in subjects with R/R CLL (Arm A) or NHL (Arm B) | Safety in long-term exposure (> 12 months) of venetoclax Second primary malignancy and Richter's transformation                                                                                                                                                                                                                                               | Interim CSR Final CSR    | September 2019 May 2021                                                |
| Study P16-562 Prospective Observational Cohort Study to Assess the Safety of Venetoclax in the Swedish Cohort of Chronic Lymphocytic Leukaemia Patients Ongoing                    | To characterize long term safety of venetoclax including determining the incidence of select adverse events in CLL patients exposed to venetoclax.                    | Safety in long-term exposure (> 12 months) of venetoclax Select list of adverse events: • Second primary malignancies • Richter's transformation (DLBCL, HL) • Opportunistic serious infections • Autoimmune hematological event o Other autoimmune hemolytic anemia o Idiopathic thrombocytopenic purpura • Tumor Lysis syndrome • Hematologic adverse event | Interim CSR Final report | Every second year over a study period of 8 years Planned December 2025 |

<div style=\"page-break-after: always\"></div>

| Study                                                                                 | Name Status                                                                                                                          | Summary of Objectives Addressed                                                                                                                                                        | Milestones    | Due Dates                                                                                                                                                      |
|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                       |                                                                                                                                      | o Anemia o Thrombocytopenia o Neutropenia • Pneumonia • Febrile Neutropenia • Diarrhea • Nausea/Vomit • Upper respiratory tract infection • Fatigue • Hyperphosphatemia • Constipation |               |                                                                                                                                                                |
| Study M16-185 Clinical drug-drug interaction study with an oral contraceptive Planned | Open-label study to assess the effect of venetoclax on the pharmacokinetics of oral contraceptive in hematologic malignancy patients | Potential DDIs with oral contraceptives                                                                                                                                                | Study planned | Date for submission cannot be specified since the Agency agreed to conduction of this study when the indication is potentially widened to a younger population |

## Risk minimisation measures

Table 30. Summary Table of Risk Minimisation Activities by Safety Concern

| Safety Concern              | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tumour lysis syndrome (TLS) | Routine risk minimisation measures: Posology and method of administration, including prophylactic measures for TLS, are described in Section 4.2 of the SmPC. Warnings and precautions for TLS are listed in Section 4.4 of the SmPC. Interaction with other medicinal products is described in Section 4.5 of the SmPC. TLS is described in Section 4.8 of the SmPC. Other routine risk minimisation measures: Prescription only medicine |

<div style=\"page-break-after: always\"></div>

| Safety Concern       | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | Use of treatment should be initiated and supervised by specialists Packaging design and language to facilitate adherence to the dose titration schedule Package leaflet Additional risk minimisation measures: None                                                                                                                                                                                                                                                                                      |
| Neutropenia          | Routine risk minimisation measures: Posology and method of administration are described in Section 4.2 of the SmPC. Warnings and precautions for neutropenia are listed in Section 4.4 of the SmPC. Neutropenia is listed as a very common adverse reaction in Section 4.8 of the SmPC. Other routine risk minimisation measures: • Prescription only medicine. • Use of treatment should be initiated and supervised by specialist • Package leaflet                                                    |
| Serious infection    | Routine risk minimisation measures: Posology and method of administration are described in Section 4.2 of the SmPC. Supportive measures for infections associated with neutropenia are described in Section 4.4 of the SmPC. Observed infections and infestations are tabulated in Section 4.8. Other routine risk minimisation measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialist • Package leaflet Additional risk minimisation measures: None |
| Embryofetal toxicity | Routine risk minimisation measures: Language concerning embryofetal toxicity is included in Section 4.6 and Section 5.3 of the SmPC. Other routine risk minimisation measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Package leaflet                                                                                                                                                                                                       |
| Medication error     | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                     | Section 4.2 of the SmPC. Language concerning overdose is included in Section 4.9 of the SmPC. Other routine risk minimisation measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Each carton will be dispensed weekly to the patient during the first 4 weeks of the dose titration • Labeling and packaging layout (immediate and outer packaging) has been designed to minimize medication errors • Package leaflet Additional risk minimisation measures: None |
| Richter's transformation                            | Routine risk minimisation measures: Posology and method of administration are described in Section 4.2 of the SmPC. Other routine risk minimisation measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialist Additional risk minimisation measures: None                                                                                                                                                                                                                   |
| Second primary malignancy                           | Routine risk minimisation measures: None • Other routine risk minimisation measures: Prescription only medicine • Use of treatment should be initiated and supervised by specialist Additional risk minimisation measures: None                                                                                                                                                                                                                                                                                              |
| Toxicity in Patients with severe hepatic impairment | Routine risk minimisation measures: Posology and method of administration of dose adjustments in patients with severe hepatic impairment are described in Section 4.2 of the SmPC. PK study results pertaining to hepatic impairment are described in Section 5.2 of the SmPC Other routine risk minimisation measures: • Prescription only medication • Use of treatment should be initiated and supervised by specialist Additional risk minimisation measures: None                                                       |
| Safety in severe renal impairment                   | Routine risk minimisation measures: Section 4.2 of the SmPC advises that safety and efficacy have not yet been established in certain populations. Other routine risk minimisation measures: • Prescription only medicine                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                             | Risk Minimisation Measures                                                                                                                                                                                                                                                                      |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | • Use of treatment should be initiated and supervised by specialists • Package leaflet Additional risk minimisation measures: None                                                                                                                                                              |
| Safety in long-term exposure (> 12 months) | Routine risk minimisation measures: Median duration of treatment is included in Section 5.1 of the SmPC Other routine risk minimisation measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists Additional risk minimisation measures: None |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly. In addition, the SmPC section 5.3 has been updated based on the results of a 4-week dose ranging study, a 6-month carcinogenicity study and two embryofoetal development (EFD) studies in mice. Minor editorial changes have been introduced throughout the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable, because the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

CLL remains the most prevalent chronic leukaemia in clinical practice. The current International Working Group for CLL (iwCLL) 2018 guidelines recommend active surveillance until disease-related symptoms develop. The prognostic factors in CLL are largely based on recurrent molecular and cytogenetic abnormalities.

## 3.1.2. Available therapies and unmet medical need

The field is evolving, with a number of drugs entering the relapsed/refractory setting and moving towards first-line, moreover with changes of recommendation category within previously untreated CLL. The role of MRD negativity in achieving deeper remissions and longer PFS (and ultimately overall survival) is taking centre stage in clinical trials. Both NCCN (latest version: 2020) and ESMO (2015, with an update in

<div style=\"page-break-after: always\"></div>

2017) segregate patients with and without del(17p)/TP53mut and fit from unfit. It is often said that elderly patients, who usually have a number of coexisting conditions of varying degrees of severity, require an effective, yet less toxic, treatment than the already available therapies. In 2019, FDA approved venclyxto in combination with obinutuzumab (Gazyvaro) for previously untreated CLL (based on CLL14 trial), as well as ibrutinib + obinutuzumab for treatment-naïve CLL/SLL patients (based on the iLLUMINATE trial).

## 3.1.3. Main clinical studies

The pivotal trial BO25323/CLL14 was a randomized, multicenter, open label, phase 3 study that evaluated the efficacy and safety of venclyxto in combination with obinutuzumab (VEN+G) versus obinutuzumab in combination with chlorambucil (GClb) for patients with previously untreated CLL with coexisting medical conditions (total Cumulative Illness Rating Scale [CIRS] score &gt; 6 or CLcr &lt; 70 mL/min, but not inferior to 30 mL/min). All the patients included required therapy (Binet stage C or symptomatic disease). After a separate safety run-in, 432 patients were randomized 1:1. Cross-over was not allowed. All patients received obinutuzumab at 1000 mg on d1 (the first dose could be split as 100 mg and 900 mg on d1 and 2), and on d8 and 15 of cycle 1, and on d1 of each subsequent cycle, for a total of 6 cycles. Patients in the VEN+G arm began the 5-week venclyxto ramp-up schedule on d22 of cycle 1 and received venclyxto 400 mg once daily from cycle 3 d1 until the last day of cycle 12. Patients randomized to the GClb arm received 0.5 mg/kg oral chlorambucil on d1 and d15 of cycles 1 to 12. Each cycle was 28 days.

The primary endpoint, Progression-free survival (PFS) was assessed by investigators and by an Independent Review Committee (IRC) using the International Workshop for Chronic Lymphocytic Leukemia (IWCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008).

## 3.2. Favourable effects

At data cutoff, 30 (13.9%) PFS inv. events were registered in VEN+G arm vs 77 (35.6%) in GClb arm. Of those, 14, compared with 69, were events of disease progression. The HR for PFS-inv. was 0.35 (0.230.53).

At end of treatment visit, 123 patients (56.9%) in the VEN+G arm had achieved bone marrow MRD negativity and 163 (75.5%) peripheral blood MRD negativity, compared with 37 patients (17.1%) and 76 patients (35.5%), respectively, in the GClb arm. Twelve months after the completion of treatment, MRD negativity rates in peripheral blood were 58% (126/216) in patients treated with VEN+G and 9% (20/216) in patients treated with GClb. In CR/CRi patients, the MRD-negativity rates at end of treatment were higher for VEN+G than for GClb: bone marrow 73 (33.8%) vs 23 (10.6%); peripheral blood: 91 (42.1%) vs 31 (14.4%).

The available PFS and MRD data support an effect across cytogenetic subgroups and mutational status. The CR was 107 (49.5%) vs 50 (23.1%); ORR 183 (84.7%) vs 154 (71.3%). At the time of the cut-off, less than 10% of the study population had an OS event.

## 3.3. Uncertainties and limitations about favourable effects

Although the maturity of PFS events is relatively low, and time-related secondary endpoints including OS are yet not informative, the treatment effect is adequately robust and consistent among subgroups; there are no uncertainties on the favourable effects.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

In the VEN+G arm, fatal adverse reactions that occurred in the absence of disease progression and with onset within 28 days of the last study treatment were reported in 4/212 of patients vs. 2 /216 in GClb arm (all infections).

Serious adverse reactions were reported in 49% of patients in the VEN+G arm and 42% in the GClb arm.

In the VEN+G arm, adverse reactions led to treatment discontinuation in 16% of patients (15.4 in GClb), dose reduction in 21% (8.4% in GClb), and dose interruption in 74% (68% in GClb).

In the VEN+G arm, neutropenia led to dose interruption of venclyxto in 41% of patients, reduction in 13%, and discontinuation in 2%.

## 3.5. Uncertainties and limitations about unfavourable effects

There were no uncertainties about the unfavourable effects

## 3.6. Effects Table

## Effects Table for Venclyxto (data cut-off: August 2018)

| Effect                                                                                                                                                                                                                  | Short description                                                                                                                                                                                                       | Treatment                                                                                                                                                                                                               | Control                                                                                                                                                                                                                 | Uncertainties / Strength of evidence                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects                                                                                                                                                                                                      | Favourable Effects                                                                                                                                                                                                      | Favourable Effects                                                                                                                                                                                                      | Favourable Effects                                                                                                                                                                                                      | Favourable Effects                                                                                                                                                                                                      |
|                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | VEN+G n=216                                                                                                                                                                                                             | GClb n=216                                                                                                                                                                                                              |                                                                                                                                                                                                                         |
| PFS inv.                                                                                                                                                                                                                |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | no. of events                                                                                                                                                                                                           | 30 (13.9%)                                                                                                                                                                                                              | 77 (35.6%)                                                                                                                                                                                                              | Immature PFS data, however 17 months of off-treatment follow-up in both arms.                                                                                                                                           |
|                                                                                                                                                                                                                         | -DP                                                                                                                                                                                                                     | 14                                                                                                                                                                                                                      | 69                                                                                                                                                                                                                      |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | -death                                                                                                                                                                                                                  | 16                                                                                                                                                                                                                      | 8                                                                                                                                                                                                                       |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | median (mo)                                                                                                                                                                                                             | NE                                                                                                                                                                                                                      | NE                                                                                                                                                                                                                      |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | HR                                                                                                                                                                                                                      | 0.35 (0.23-0.53)                                                                                                                                                                                                        | 0.35 (0.23-0.53)                                                                                                                                                                                                        | PFS IRC 0.33                                                                                                                                                                                                            |
| ORR                                                                                                                                                                                                                     |                                                                                                                                                                                                                         | 183 (84.7%)                                                                                                                                                                                                             | 154 (71.3%)                                                                                                                                                                                                             | Diff 13.43% (5.47-21.38)                                                                                                                                                                                                |
| CR                                                                                                                                                                                                                      |                                                                                                                                                                                                                         | 107 (49.5%)                                                                                                                                                                                                             | 50 (23.1%)                                                                                                                                                                                                              | Diff 26.39% (17.41-35.36)                                                                                                                                                                                               |
| MRD                                                                                                                                                                                                                     | PB                                                                                                                                                                                                                      | 163 (75.5%)                                                                                                                                                                                                             | 76 (35.2%)                                                                                                                                                                                                              |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | Marrow                                                                                                                                                                                                                  | 123 (56.9%)                                                                                                                                                                                                             | 37 (17.1%)                                                                                                                                                                                                              |                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         | PB in CR patients                                                                                                                                                                                                       | 91 (42.1%)                                                                                                                                                                                                              | 31 (14.4%)                                                                                                                                                                                                              | MRD correlation with PFS                                                                                                                                                                                                |
| Unfavourable Effects                                                                                                                                                                                                    | Unfavourable Effects                                                                                                                                                                                                    | Unfavourable Effects                                                                                                                                                                                                    | Unfavourable Effects                                                                                                                                                                                                    | Unfavourable Effects                                                                                                                                                                                                    |
| Observe that in clinical praxis GClb is administered for 6 cycles, with no chlorambucil monotherapy for another 6 cycles, as done in CLL14 for regulatory purposes (to obtain same duration of treatment in both arms). | Observe that in clinical praxis GClb is administered for 6 cycles, with no chlorambucil monotherapy for another 6 cycles, as done in CLL14 for regulatory purposes (to obtain same duration of treatment in both arms). | Observe that in clinical praxis GClb is administered for 6 cycles, with no chlorambucil monotherapy for another 6 cycles, as done in CLL14 for regulatory purposes (to obtain same duration of treatment in both arms). | Observe that in clinical praxis GClb is administered for 6 cycles, with no chlorambucil monotherapy for another 6 cycles, as done in CLL14 for regulatory purposes (to obtain same duration of treatment in both arms). | Observe that in clinical praxis GClb is administered for 6 cycles, with no chlorambucil monotherapy for another 6 cycles, as done in CLL14 for regulatory purposes (to obtain same duration of treatment in both arms). |
|                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | n=212                                                                                                                                                                                                                   | n=214                                                                                                                                                                                                                   |                                                                                                                                                                                                                         |
| Interruption                                                                                                                                                                                                            | Interruption                                                                                                                                                                                                            | 73.6%                                                                                                                                                                                                                   | 68.2%                                                                                                                                                                                                                   | VEN+G: 41% were due to neutropenia                                                                                                                                                                                      |
| Dose reduction                                                                                                                                                                                                          | Dose reduction                                                                                                                                                                                                          | 20.8%                                                                                                                                                                                                                   | 8.4%                                                                                                                                                                                                                    | VEN+G: 13% were due to neutropenia                                                                                                                                                                                      |
| Discontinuation                                                                                                                                                                                                         | Discontinuation                                                                                                                                                                                                         | 16%                                                                                                                                                                                                                     | 15.4%                                                                                                                                                                                                                   | VEN+G: 2% were due to neutropenia                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Effect                      | Short description              | Treatment                   | Control                     | Uncertainties / Strength of evidence                                                 |
|-----------------------------|--------------------------------|-----------------------------|-----------------------------|--------------------------------------------------------------------------------------|
| AEs>10% (all grades/Gr≥3) % | AEs>10% (all grades/Gr≥3) %    | AEs>10% (all grades/Gr≥3) % | AEs>10% (all grades/Gr≥3) % | AEs>10% (all grades/Gr≥3) %                                                          |
|                             | Neutropenia                    | 60/56                       | 62/52                       | Gr 3-4 febrile neutropenia 5.2 vs 3.7 Gr 3-4 infections 17.5 vs 15 GCSF 43.5 vs 45.8 |
|                             | Anemia                         | 17/8                        | 20/7                        |                                                                                      |
|                             | Diarrhea                       | 28/4                        | 15/1                        |                                                                                      |
|                             | Nausea                         | 19/0                        | 22/1                        |                                                                                      |
|                             | Constipation                   | 13/0                        | 9/0                         |                                                                                      |
|                             | Vomiting                       | 10/1                        | 8/1                         |                                                                                      |
|                             | Fatigue                        | 21/2                        | 23/1                        |                                                                                      |
|                             | upper resp. tract infection    | 17/1                        | 17/1                        |                                                                                      |
| SAEs                        | SAEs                           | 104 (49.1%)                 | 90 (42.1%)                  | Infection: 18.9% vs 14%                                                              |
| Deaths                      | all-cause mortality            | 20 (9.4%)                   | 16 (7.5%)                   |                                                                                      |
|                             | fatal AEs                      | 16 (7.5%)                   | 8 (3.7%)                    | Treatment-related infection: 4 vs 2 patients                                         |
|                             | -on treatment                  | 5                           | 4                           |                                                                                      |
|                             | -after completion of treatment | 11                          | 4                           |                                                                                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

CLL patients, who usually have a number of coexisting conditions of varying degrees of severity, require an effective, yet less toxic, treatment than the already available therapies. In the pivotal study CLL14, PFS outcomes were supported by MRD results and other secondary endpoints. A fixed duration of one year of treatment seems sufficient to allow deep and prolonged control of disease. However, the proposed regimen is not less toxic than GClb. Although no new safety concerns for venclyxto were identified, neutropenia, leading to severe infections, some fatal, dominate the safety profile of the VEN+G combination. Nevertheless, as most infections can be managed adequately in the clinical setting if promptly identified and treated, the effect of the combination of venclyxto and obinutuzumab is considered to outweigh the risk of infection.

## 3.7.2. Balance of benefits and risks

The applicant is seeking an indication for first-line treatment of CLL regardless of age or comorbidities. While the patients included in study CLL14, with a median age of 72 and a median CIRS score of 8, might be regarded as representative for most CLL patients, patients considered fit for e.g. FCR were not studied. However, extrapolation of efficacy also to younger and more fit patients is considered acceptable. This is since the safety profile in such patients is not anticipated to be less favourable; furthermore, the effect size demonstrated, although not directly compared with FCR, is considered sufficient to make venetoclax + obinutuzumab a reasonable first line treatment alternative, where the differential safety profile comparted to chemotherapy is notable. The inclusion criteria for the pivotal study (i.e. patients with coexisting conditions) are reflected in section 5.1 of the SPC.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Venclyxto in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4                 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I                  |
| C.I.4                 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I                  |
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include, in combination with an anti -CD20 antibody (obinutuzumab), treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) for Venclyxto based on the results of the pivotal CLL14/BO25323 phase 3 study; consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC and corresponding sections of the PL have been revised. The updated RMP version 5.4 has been agreed. Additionally, the SmPC section 5.3 has been updated based on the results of a 4-week dose ranging study, a 6-month carcinogenicity study and two embryo-foetal development (EFD) studies in mice. Minor editorial changes have been introduced throughout the Product Information.

The group of variations leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Venclyxto is not similar to Gazyvaro (obinutuzumab) and Imbruvica (ibrutinib) within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000. See appendix 1.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this group of variations. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

<div style=\"page-break-after: always\"></div>

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Venclyxto-H-C-4106-II-23-G